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Abstract 
There are many energy metabolism studies ongoing, including those for cardiovascular diseases 
and type-2-diabetes. With an increase in people being diagnosed with type-2-diabetes, there 
should be more ways to monitor not only the blood glucose levels but also the other biomarkers 
associated with type-2-diabetes. The metabolism biomarkers are essential in understanding the 
cause of diabetes early on. These biomarkers include: glucose, non-esterified fatty acid, lactate, 
urea, creatinine, glycosylated haemoglobin and cholesterol. Whilst glucose measurement has a 
clear role in type-2-diabetes management, the potential value of non-esterified fatty acid has not 
been explored or highlighted yet. 
The aim of this project is to develop an electrochemical biosensor for the non-esterified fatty 
acid in human blood, as non-esterified fatty acid can cause -cell loss in type-2-diabetes. 
Exploration of this biomarker would be a step forward in increasing research and patient 
understanding of the dynamic processes involved in establishing good metabolism control. 
The project uses the enzymes in commercial optical methods for non-esterified fatty acid 
detection. Oleic acid was used as the standard non-esterified fatty acid in this work. The 
electrochemical techniques employed are cyclic voltammetry, linear sweep voltammetry, 
chronoamperometry and electrochemical impedance spectroscopy. 
Enzyme electrodes were fabricated using the layer-by-layer immobilization of alternating 
polymer and enzyme combinations on carbon, cobalt phthalocyanine and single wall carbon 
nanotube screen printed electrodes. A chronoamperometric non-esterified fatty acid sensor was 
developed with the linear detection range of 0.10 mM to 0.90 mM oleic acid and with a 
sensitivity of 0.6562 A/mM oleic acid. This sensor was then further fabricated to detect non-
esterified fatty acid concentrations in human plasma and serum samples. Commercial UV optical 
methods were used as method of validation of the blood sample concentrations. This work 
produced a platform for further non-esterified fatty acid detection studies. 
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1 Background and literature review part 1 
1.1 Background 
Diabetes mellitus is a typical disease of metabolism disorder [1]. Approximately 10 % of the 
annual NHS budget (~£9 billion), is spent on treating diabetes and its subsequent complications. 
It is the leading single expenditure for the NHS. According to Diabetes UK approximately over 4 
million people are predicted to have diabetes by the year 2025 [2]. Mostly being type-2-diabetes 
(T2D), this is caused by the ageing population and large increase in overweight and obese 
people. These people are in danger of short and long term illnesses, such as cardiovascular 
events and renal malfunction [3]. Diabetes poses a major and growing health and socio-economic 
burden on society [4].  
 
T2D is a chronic metabolic disorder, characterised by insulin resistance, hyperglycemia, 
hyperinsulinemia and elevated plasma non-esterified fatty acid (NEFA) and glucose 
concentrations, with poor glycemic control associated with an increased risk of heart failure [5]. 
With obesity having reached epidemic proportions in many countries and due to the close 
relationship between obesity and T2D, an epidemic of diabetes is expected to follow [6]. The 
vast majority diagnosed with T2D are obese. Obesity arises from an energy imbalance where 
energy intake exceeds energy expenditure. Dealing with obesity requires modification of one or 
both components of energy balance. A key drawback is the lack of suitable biomarkers to assess 
the power/use of different treatments on components of energy balance. 
 
Assessment of NEFA may be a useful addition to routine diabetes management. NEFA, like 
glucose can reflect acute change of an individual’s energy status. Glucose and NEFA are 
biomarkers of immediate energy metabolism. There are many glucose biosensors, but there is a 
need to develop a biosensor for NEFA measurements. Conventional glucose measurements 
provide patients with some information, but combining that with NEFA will give the patient a 
fuller picture on what is going on in their body with regards to their insulin resistance and insulin 
sensitivity. 
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The ideal NEFA sensor is required to be selective for NEFA with a fast, predictable response to 
shifting NEFA concentrations [7]. This must rely on a signal that is reversible and reproducible. 
The fabrication of the sensor ought to be cost efficient when applied to a large scale. It is crucial 
to have a lengthy operational lifetime under physiological conditions, yet most importantly it has 
to be tolerable for the patient. For that reason, the biosensor should not require user calibration 
and preferably offer real-time continuous information concerning NEFA. Fast diagnosis along 
with early prevention are critical in controlling T2D [8].  
 
Conditions for a successful biosensor [9]: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific biocatalyst 
 
Reaction free of 
physical factors 
(e.g. pH and 
temperature) 
 
Accurate, precise 
and reproducible 
response 
 
For invasive monitoring use in 
clinical settings, the probe of the 
biosensor has to be small and 
biocompatible, without any lethal 
or antigenic effects 
 
Real-time analysis for fast 
measurements of analytes from 
human samples 
 
Usable by semi-
skilled operators 
 
Biosensor 
Stable in standard 
storage conditions 
 
Low variation between 
assays 
 
Small and portable 
 
Cost-efficient on 
large scale 
 
Linear in the 
concentration range of 
interest, not needing 
diluting or concentrating 
 
3 
 
1.2 NEFA - Literature review part 1 
1.2.1 NEFA and its role 
Over the last 5 years there have been ~150 papers published per year on NEFA as shown in 
Figure 1-1. This search was carried out using the database web of knowledge. The topic searched 
was ‘non-esterified fatty acid’ for the years 2009-2013. Only articles in English were included 
and studies that had repeat publications were counted as one. 
 
 
Figure 1-1: NEFA publications over the last 5 years. 
Most frequently NEFA is measured in animals (especially mammals) rather than humans, 61-72 
% vs. 17-29 % respectively (over the last 5 years). As NEFA is also a metabolism biomarker for 
lactating cows, this is another big market for NEFA biosensor development. In literature the 
other animals that NEFA is detected in are; rat, mice, sheep, water buffalo, bull, camel, cats, 
chicken, dogs, goat, hamsters, horses, pig, rabbit, elephant seal, squirrel and birds. Animal 
models in rats and mice have been used extensively as they relate to human energy metabolism 
states, plus certain things/studies that can be done in using animal models cannot be done with 
humans. An example of this would be fasting for 6 days, which can be ethically approved for 
animal studies only [10]. The breakdown of the topics of published papers per year is given in 
the pie charts in Figure 1-2. The papers published came under 8 sections. The section titled 
‘General literature’ was created as there were some papers published on general information on 
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NEFA (including its use in biodiesel applications) which does not fall under any of the main 
categories for NEFA detection. This was the smallest section, only accounting for 2-4 % of the 
total. 
 
 
 
 
Figure 1-2: Pie charts showing the percentage distribution of the topics of publications regarding NEFA over the last 5 
years. 
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NEFA in humans has been detected in plasma/serum for two main reasons: 
1. Energy metabolism studies – such as metabolic syndrome [11, 12], obesity [13, 14], T2D 
[15-19], insulin resistance [20, 21], atherosclerosis [22-24], cardiovascular studies [25-
27] and non-alcoholic fatty liver disease [28-30]. Other diseases include; cystic fibrosis 
[31], thyroid [32, 33], Alzheimer’s [34, 35], multiple sclerosis [36, 37], schizophrenia 
[38], Rett syndrome [39], kidney function [40]  and gallstone formation [41]. 
2. Exercise studies – in which NEFA is used as a substrate to provide energy during 
exercise [42-46]. 
 
NEFA levels have also been measured in pregnant women because the development and growth 
of the foetus depends on transport of fatty acids from the circulation of the mother’s blood [47, 
48]. Increase in NEFA levels are linked to maternal obesity which gives an exaggerated lipid 
response and higher insulin resistance, indicating a risk of future obesity in the unborn offspring 
[48]. Women generally have higher NEFA levels compared to men but are more insulin sensitive 
with better lipid profiles in comparison [49]. 
 
There have also been some publications on using Chinese herbal medications for treatment in 
metabolic syndrome, in which NEFA is a biomarker that is assessed routinely [50, 51]. These 
papers came under ‘Human metabolism studies’ too. Giving a total of 16-27 % share of the 
published literature in that section over the last 5 years. 
 
There have been a few ways of detection and quantification of NEFA levels, including 
techniques such as NMR [52-54], flow cytometry [55], GC-MS [56-58], LC [59, 60], HPLC 
[61], fluoroimmunoassay [62], supercritical fluid extraction [63], GC-MS and GC-FTIR [64]. 
Obviously these came under the ‘Detection of NEFA’ section, with a minor 5-11 % of the 
overall papers published. 
 
NEFA are highly hydrophobic, shunning the aqueous medium of body fluids [65]. They are 
generally toxic to cells and are metabolically kept at low nanomolar or micromolar 
concentrations in plasma. When NEFA are not attached to other molecules they are known as 
free fatty acids (FFA’s) [66]. They are transported while being bound to plasma protein albumin 
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[67]. The levels of NEFA in the blood are restricted by the availability of albumin binding sites. 
Specific dietary fatty acids may raise total serum cholesterol levels and low-density lipoprotein 
(LDL) cholesterol levels [68]. Fatty acids are metabolic substrates for producing energy, 
precursors for many lipid species and substrates for the acylation of proteins [22]. 
 
The pattern of NEFA concentrations in blood is interesting for a variety of biochemical and 
clinical investigations both in animals and humans. NEFA make up approximately 10 % of the 
total blood fatty acids, usually 0.5 - 2.0 mmol/L [69]. The plasma concentration increases during 
periods of fasting as fatty acids are released from adipose tissue for use as metabolic fuel. The 
oxidation of fatty acid is increased 2.5 times during fasting [70]. In fasting NEFA is the energy 
source for most tissues (peripheral – heart, skeletal muscle and liver) except the brain and red 
blood cells [71]. Typical plasma NEFA levels are ~ 0.3 – 0.6 mmol/L after overnight fasting, and 
up to 1.3 mmol/L after 72 hours of fasting [49]. In other literature plasma NEFA concentration is 
stated to be between the range of 0.1 – 1.0 mmol/L [72]. Parallel to this, there have been 
significant increases in NEFA blood levels reported (up to 1.143 mmol/L higher than at rest) 
during stressful periods (that is mental and emotional stress) in humans [73, 74]. Palmitic acid 
accounts for ~ 30 % of the total NEFA pool independently of the plasma NEFA concentration 
[75].  
 
Elevated plasma NEFA levels are predictive/indicative of obesity, T2D, hypertension, 
dyslipidemia, atherosclerotic vascular disease, non-alcoholic fatty liver disease, sudden death 
and cancer mortality [49, 72, 76-81]. The elevation increases as adipose tissue accumulates, 
particularly with abdominal obesity [72]. The type of fat consumed may alter the NEFA pool in 
plasma [82]. This affects both short and long term NEFA composition of the human diet. The 
common NEFAs that have been investigated in NEFA studies are listed in Table 1-1. 
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Table 1-1: Common NEFAs and their structures [67, 83-85] 
NEFA 
Chain 
formula 
Chemical 
formula 
Structure 
Lauric acid C12:0 C12H24O2 
 
Myristic acid C14:0 C14H28O2 
 
Palmitic acid C16:0 C16H32O2 
 
Palmitoleic acid C16:1 cis C16H30O2 
 
Stearic acid C18:0 C18H36O2 
 
Oleic acid C18:1 cis C18H34O2 
 
Vaccenic acid C18:1 trans C18H34O2 
 
Linoleic acid C18:2 cis C18H32O2 
 
Arachidic acid C20:0 C20H40O2 
 
Arachidonic acid C20:4 cis C20H32O2 
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1.2.2 NEFA in human blood 
The blood plasma of an average 70 kg man contains 50 milliequivalent per litre (mEq/L) of fatty 
acids (25 mEq/L in phospholipids, 12 mEq/L in cholesterol esters, 10 mEq/L in triglycerides and 
3 mEq/L in NEFA) [86]. Fatty acids are stored as triacylglycerols, which are our principle 
energy reserves [87]. As can be seen from Table 1-2 the potential energy stored in 
triacylglycerols in the average person exceeds that which is stored anywhere else. Stored fuels 
serve to meet caloric needs during starvation for 1 to 3 months, whereas carbohydrate reserves 
are exhausted in 1 day [88]. NEFA is the major fuel during long periods between meals [89]. 
NEFA are also a major fuel for muscle contraction in light to moderate exercise and for longer 
periods of exercise [90]. Whilst exercising the NEFA concentration is 2 to 3 times higher than it 
is at rest [91-93]. The triacylglycerol/fatty acid substrate cycle regulates lipid metabolism [70]. 
Table 1-2: Fuel reserves in a typical 70 kg man [88]. 
 Available energy in kcal (kJ) 
Organ Glucose or glycogen Triacylglycerols Mobilizable proteins 
Blood 60 (250) 45 (200) 0 (0) 
Liver 400 (1,700) 450 (2,000) 400 (1,700) 
Brain 8 (30) 0 (0) 0 (0) 
Muscle 1,200 (5,000) 450 (2,000) 24,000 (100,000) 
Adipose tissue 80 (330) 135,000 (560,000) 40 (170) 
 
There is an early rise in blood triglyceride concentrations minutes after having a meal that 
contains fat [94]. Diets high in fat are associated with obesity, T2D and atherosclerosis. Another 
side effect of obesity is non-alcoholic fatty liver disease. In obesity-related insulin resistance, the 
oxidation of fatty acid is reduced. 
 
There are 3 stages of mitochondrial oxidation of fatty acids [95]: 
1. -oxidation of the fatty acids - the oxidative removal of two-carbon units successively as 
acetyl-Coenzyme A (acetyl-CoA). 
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2. Acetyl-CoA’s acetyl residues are oxidized to CO2 in the citric acid cycle (also known as 
the tricarboxylic acid or Kreb’s cycle) in the mitochondrial matrix. 
3. Electrons derived from the 1st two stages are passed to O2 in the mitochondrial respiratory 
chain; this provides energy for ATP synthesis by oxidative phosphorylation. 
In the 1
st
 stage for palmitic acid (carbon-16, typical saturated fatty acid as an example), seven 
passes are undergone through this oxidative sequence using 4 enzyme-catalysed reactions 
(shown in Figure 1-3), losing 2-carbons as acetyl-CoA each time. The equation for the 1
st
 pass is: 
     Palmitoyl-CoA + CoA + FAD + NAD
+
 + H2O  myristoyl-CoA + acetyl-CoA + FADH2 + NADH + H
+
 
7 more passes through this sequence oxidizes one molecule of palmitoyl-CoA to 8 molecules of 
acetyl-CoA. The overall equation: 
     Palmitoyl-CoA + 7CoA + 7FAD + 7NAD
+
 + 7H2O  8acetyl-CoA + 7FADH2 + 7NADH + 7H
+
 
Including the electron transfers and oxidative phosphorylation: 
     Palmitoyl-CoA + 7CoA + 7O2 + 35Pi + 35ADP  8acetyl-CoA + 35ATP + 42H2O 
The 2
nd
 stage, together with the coupled phosphorylations of the 3
rd
 stage gives: 
     Palmitoyl-CoA + 16O2 + 96Pi + 96ADP  8CoA + 96ATP + 104H2O + 16CO2 
Overall equation for palmitoyl-CoA’s complete oxidation to CO2 and H2O: 
     Palmitoyl-CoA + 23O2 + 131Pi + 131ADP  CoA + 131ATP + 146H2O + 16CO2 
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Figure 1-3: Palmitoyl-CoA oxidation. 
 
The oxidation of monounsaturated fatty acyl-CoA’s (e.g. oleoyl-CoA) require an additional 
enzyme, enoyl-CoA isomerise (Figure 1-4). This enzyme converts the cis isomer to trans isomer. 
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Figure 1-4: Oleoyl-CoA oxidation. 
 
The acetyl-CoA generated from the oxidation of glucose and NEFA is then further metabolized 
by the citric acid cycle [96]. In the cycle two things happen, phase 1 (reactions 1-4) oxidize two 
carbons to CO2, phase 2 (reactions 5-8) regenerates oxaloacetate [97]. This is illustrated in 
Figure 1-5. Four oxidation reactions occur. The coenzyme for 3 of the reactions was 
nicotinamide adenine dinucleotide (NAD
+
) and for 1 was flavin adenine dinucleotide (FAD). 
The structure of FAD is shown in Figure 1-6. FAD undergoes two electron oxidation and 
reduction reactions (Figure 1-6). Having an intermediate of semiquinone free radical results in 
these reactions occurring one electron at a time. Reduced flavin adenine dinucleotide (FADH2) 
and reduced nicotinamide adenine dinucleotide (NADH) then transport energy to the 
mitochondrial electron transport chain (ETC) [96]. This is where oxidative phosphorylation 
happens. 
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Figure 1-5: Citric acid cycle [97, 98]. 
  
Figure 1-6: Full Structure of FAD and FAD oxidation and reduction reactions [97]. 
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Once the acetyl-CoA formed (-oxidation in the liver), exceeds the capacity of the citric acid 
cycle, that excess forms ketone bodies, as in acetone, acetoacetate and D--hydroxybutyrate 
[99]. This happens in severe, uncontrolled diabetes. Diabetics oxidize large amounts of fatty acid 
instead as glucose is not used efficiently. The activity of the citric acid cycle is therefore reduced 
and acetyl-CoA accumulates. 
 
1.2.3 NEFA, obesity and prevention of T2D 
Diets containing high levels of saturated fats lead to obesity and insulin resistance, and increase 
levels of circulating NEFAs [4, 79]. In addition, they contribute to pancreatic -cell failure in 
genetically predisposed individuals. NEFAs cause -cell apoptosis and may thus contribute to 
progressive -cell loss/damage in T2D (Figure 1-7) [4]. NEFA concentration in blood is a 
biomarker for diabetes. Once diabetic, the plasma NEFA levels show linear correlation with 
blood glucose and hepatic glucose production (in both lean and obese individuals) [100]. Cross-
talk between adipocytes and β-cells is mediated by NEFA and adipocyte secreted adipokines [4]. 
High concentrations of circulating NEFAs (especially saturated NEFAs) and low adiponectin 
levels are predictive of developing diabetes. NEFA and adipokines play a direct role in 
pancreatic -cell failure in T2D.  
 
Prolonged increase of circulating NEFAs by lipid infusion damages the task of pancreatic -cells 
in vivo, especially in people with a genetic predisposition to T2D. People with T2D in the family 
are 2-6 times more susceptible to developing it than people without [101, 102]. After myocardial 
infarction, NEFA has been stated responsible for ventricular arrhythmias and is strongly 
correlated with heart rate and blood pressure [103]. Lipotoxicity has damaging effects of 
regularly elevated NEFA by reducing the secretion of insulin, diminishing insulin synthesis and 
-cell apoptosis [16]. Preventing -cells from exposure to high serum levels could delay the 
progression of T2D. During morning hours, high levels of NEFA and very low density 
lipoproteins relate to prevalence of heart attacks being most frequent [74]. 
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Figure 1-7: Model for the effects of adipocytes on pancreatic -cell function/mass and insulin sensitivity in the 
pathogenesis of T2D [4]. IR = insulin resistance. 
 
NEFA is considered to link obesity with insulin resistance and T2D [104, 105]. Weight loss of 
~5 % in people at risk of developing T2D cuts the risk in half [6]. The factors that contribute to 
cardiovascular disease are shown in the appendix in Figure 7-1. National Institute of Health 
(1998) issued obesity treatment guidelines proposing a 10 % weight loss. Currently there are two 
ways to reverse T2D, that is either by surgery (bariatric gastric band) or by lifestyle interventions 
(diet – calorie restriction and exercise) [106, 107]. Studies have been done to explore the lifestyle 
intervention option by many including the Finnish Diabetes Prevention Study Group, groups also 
in China, Sweden and in UK by Professor Roy Taylor’s Group based at Newcastle University 
[108-111].  In the latter study, 11 patients who had T2D (for a period < 4 years) were put on a 
600 kcal/day diet for 8 weeks [111]. Multiple variables (such as weight, BMI and waist 
circumference) and metabolism biomarkers (including glucose, NEFA and cholesterol) were 
monitored, after weeks 1, 4 and 8. At the end of the study, following the diet, normal -cell 
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function and glucose levels were restored. The NEFA levels were reduced from 0.93 mM at 
week 1 to 0.81 mM at week 4 to 0.72 mM at week 8, compared to the controls (0.57 mM).  
Commercial UV NEFA detection method was used in the study. Having a NEFA 
electrochemical sensor would be useful for research in lifestyle interventions such as this. This 
research encouraged the public to share their weight loss and T2D reversal experience [112].  61 
% of this population studied was successful, with minimal/no support from healthcare 
practitioners. As there is no commercial NEFA sensor at the moment, these self-monitoring 
home patients used fasting capillary blood glucose and glycosylated haemoglobin (HbA1c) as 
methods of measurement for their T2D. Glucose meters and glycohaemoglobin test-kits are used 
as they are the two foremost indicators in diabetes diagnosis and long-term management [8]. 
More long-term studies have been done by the Look AHEAD Research group, in which the 
NEFA concentrations have significantly decreased with weight loss over a longer time [113, 
114]. 
 
1.2.4 Current methods of NEFA detection 
1.2.4.1 Initial methods 
For NEFA detection most investigators have employed palmitate and/or oleate as their fatty 
acids of choice, probably because these two fatty acids represent the major species present in 
human serum and therefore, they are the principal molecules to which β-cells might be exposed 
to in vivo [115]. 
NEFA detection in blood can be dated back to the late 1950s [116-120]. The methods developed 
during this time can be classified into four groups [121]:  
(a) colorimetric titration of NEFA in the presence of a pH indicator [122-124] 
(b) spectrophotometric or radiochemical measurements of complexes of NEFA with divalent 
metal ions such as Cu 
2+
, Ni 
2+
 or Co 
2+
 [125] 
(c) colorimetric assays based on a reaction between NEFAs [126] 
(d) radiochemical assay of NEFA [127, 128] 
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These methods, however, were either laborious, time-consuming or showed a lack of good 
sensitivity. Of these methods only colorimetric and radioassay methods met the requirements for 
a small sample volume with radioassay requiring specialised equipment and radioisotope 
handling [129].  
Several molecules were found to cause interference with NEFA level determination, namely, 
phospholipids, bilirubin, albumin, haemoglobin, lecithin, lactic acid, acetic acid, ascorbic acid, 
-hydroxybutyric acids, triglycerides, glutathione, cysteine and unreacted CoA [118, 121, 125, 
127, 129-132]. These will be discussed in detail later. 
 
1.2.4.2 NEFA multiple enzyme biosensor development 
In 1989, Sode et al developed two NEFA sensors. The first biosensor was developed following 
the reaction in Figure 1-8 [133]. The measurement was based on monitoring dissolved O2 
consumed by the two sequential reactions catalysed by the enzymes immobilized in photo-cross-
linked polyvinyl alcohol. They were entrapped on a cellulose nitrate membrane, which was then 
placed over a Teflon membrane of a Clark-type membrane O2 sensor [134]. The two enzymes 
used were acyl-Coenzyme A synthetase (ACS) and acyl-Coenzyme A oxidase (ACOD). 
 
Figure 1-8: Reaction scheme of the enzymatic determination of NEFA [133]. 
 
Aqueous emulsions of oleic and palmitic acid were tested. The biosensor was linear from 0.38 to 
2.0 mM for oleic acid and to 2.6 mM for palmitic acid and was stable and usable for three days. 
 
The second amperometric sensor was developed using 5 sequential enzyme reactions (Figure 
1-9) for the measurement of NEFA in oily foods [135]. The sensitivity of the sensor towards 
oleic acid was 0.046 A/mM and for palmitic acid was 0.039 A/mM. Further improvement of 
the sensor was essential for its use in clinical analysis. 
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Figure 1-9: Sensor based on 5 sequential enzyme reactions [135]. 
 
1.2.4.3 Current clinical NEFA detection 
Many companies worldwide (including; Wako Diagnostics, Roche Applied Science, Zen-Bio 
Inc. and Randox) have developed an enzymatic method to detect the amount of NEFA in a given 
sample of blood. All enzymatic methods rely upon the acylation of coenzyme A (CoA) by the 
NEFA in the presence of added enzyme ACS. The acylated CoA (acyl-CoA) is then oxidized by 
added enzyme ACOD with the generation of hydrogen peroxide (H2O2). In the presence of 
peroxidase (POD) this H2O2 allows the oxidative condensation of another compound to form a 
coloured dye which is then measured colorimetrically at a particular wavelength. There are 
different coloured dyes produced depending on which compounds as dye the companies use, and 
their respective absorbance is measured at wavelengths accordingly.  
Figure 1-10 shows the enzymatic reactions used in the different assays for NEFA detection. 
Table 1-3 summarizes the information provided commercially by the same companies. These 
kits are explicitly for research use only and are not to be used for diagnostic procedures, as stated 
in the leaflet of instructions provided. The use of ascorbate oxidase and N-ethyl-maleinimide 
(NEM) in some kits is for elimination of interferences from ascorbic acid or excess CoA, 
respectively. 
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Figure 1-10: Different assay schemes used for NEFA detection (colorimetric methods are shown in red, fluorometric in green) [136-146].
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Table 1-3: The companies/methods for NEFA detection on the market currently. 
 
 
 
Company 
name 
Method of 
detection 
Serum/
plasma 
Used for? 
Standard 
used 
Detection 
range 
(mmol/L) 
Ascorbate 
oxidase? 
NEM
? 
Measured 
wavelength 
(nm) 
Reference 
Roche Applied 
Science 
Colorimetric Both Humans 
Palmitic 
acid 
Up to 1.5 Yes Yes 546 [142] 
Wako 
Diagnostics 
Colorimetric Serum Humans Oleic acid 0.01 to 4 No No 550 [143] 
Zen-Bio Inc. Colorimetric Both 
Humans, 
mice, rats and 
other animals 
Oleic acid 0.333 to 1 No No 540 [144-147] 
Randox 
Laboratories 
Ltd. 
Colorimetric Both 
Humans, 
mice, rats and 
other animals 
Palmitic 
acid 
0.072 to 
2.24 
Yes Yes 550 [148] 
Cusabio ELISA Both Bovine 
Palmitic 
acid 
1 x 10-8 to 
4 x 10-7 
- - 450 [149] 
BioVision Inc. 
Colorimetric Both Mammalian 
Palmitic 
acid 
2 x 10-3 No No 570 [150] 
Fluorometric Both Mammalian 
Palmitic 
acid 
2 x 10-3 No No 535/590 [150] 
Shanghai 
Crystal Day 
Biotech Co. 
LTD 
ELISA Both Bovine 
Oleic/ 
palmitic/ 
stearic acids 
2 x 10-3 to 
0.6 
- - 450 [151] 
Catachem Inc. Colorimetric Both 
Humans, 
mice, rats and 
other animals 
Synthetic 
fatty acids 
0 to 2.5 Yes No 550 [136] 
Diagnostic 
systems 
Colorimetric Both Humans Oleic acid 0.01 to 3 No No 546/600 [138] 
Cell Biolabs 
Inc. 
Colorimetric Both Humans 
Palmitic 
acid 
0 to 0.5 No Yes 570 [140] 
Fluorometric Both Humans 
Palmitic 
acid 
0 to 0.5 No Yes 530/590 [141] 
Sigma-Aldrich 
Colorimetric Both Humans 
Palmitic 
acid 
1 No No 570 [152] 
Fluorometric Both Humans 
Palmitic 
acid 
1 No No 535/587 [152] 
Abcam 
Colorimetric Both Humans 
Palmitic 
acid 
2 x 10-3 No No 570 [153] 
Fluorometric Both Humans 
Palmitic 
acid 
2 x 10-3 No No 535/590 [153] 
Cayman 
Chemical 
Company 
Fluorometric Both Humans Oleic acid 0 to 0.25 Yes Yes 530/590 [137] 
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A few 96-well NEFA detection kits have been developed by the company Zen-Bio Inc. (cat # 
SFA-1/SFA-10) for increased throughput analysis [144, 145]. This was produced for ease, to 
reduce the cost of labour and supplies [154]. Zen-Bio Inc. have also developed a 96-well NEFA 
and free glycerol detection kit (cat # GFA-1) and a cellulite treatment screening kit for NEFA 
and free glycerol detection (cat # LIP-12) [146, 147]. In these two kits the method for NEFA 
detection is the same as that shown in Figure 1-10. However the glycerol is detected via the 
following reaction scheme: 
 
The increase in absorbance at 540 nm is directly proportional to the glycerol concentration of the 
given sample. 
The first two reactions in Figure 1-10 are highly specific for NEFA, but there is interference with 
the third reaction due to the incomplete selectivity of the POD [155]. The known interferences in 
these methods were; haemoglobin, ascorbic acid, uric acid, hemolysis, bilirubin, lipids, heparin, 
citrate, oxalate, ethylenediaminetetraacetic acid (EDTA), sodium fluoride and drug metabolites 
[140, 141, 143, 155, 156]. CoA is also known to interfere with the POD reaction [139]. 
Interference of excess CoA and use of NEM can be avoided by use of special trinder reagent (for 
colour change test) such as p-sulfonyl-carbethoxy pyrazolone (p-SCEP), as the company 
Diagnostic Systems based in Germany had done. In the listed assays the limits of detection vary 
from 1.5 mM to 3.0 mM NEFA, and some assays state that they are usable for urine, saliva and 
other related biological tissue liquid too.  
These commercial kits are not only expensive, but once the reagents are mixed they have to be 
used up within a month, as the enzymes have a limited lifetime. The assays do take a long time 
to complete if done individually. However for doing long term studies of NEFA concentrations 
in humans/animals, these kits are not ideal. 
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1.2.5 The role of NEFA in other disease states 
1.2.5.1 Refsum’s disease 
Mitochondrial disorders affect metabolically active tissues right through the body [157]. The 
determination of percentage composition of individual NEFA in plasma is important when 
investigating metabolic disorders involving fatty acids, like in Refsum’s disease [158]. Refsum’s 
disease is a rare autosomal recessive disorder (prevalence is 1 in 10
6
 people) [159]. Typical 
characteristics of this disease include retinitis pigmentosa, progressive deafness, anosmia, 
peripheral neuropathy, cerebellar ataxia, skin changes, cardiac complications (in later life) and 
skeletal abnormalities [159, 160]. 
Refsum’s disease is a disorder of the metabolism of phytanic acid, which consists of 20 carbons, 
multibranched (3,7,11,15-tetramethylhexadecanoic acid), structure is shown in Figure 1-11 
[160].  
 
Figure 1-11: Chemical structure of Phytanic acid. 
Phytanic acid is virtually undetectable in normal plasma (< 10 mol/L), but in patients with the 
disease the plasma concentration of the fatty acid becomes > 200 mol/L [161]. Other 
peroxisomal diseases in which phytanic acid is increased are:  
 -methylacyl-CoA racemace (AMACR) deficiency 
 peroxisomal biogenesis disorders 
 rhizomelic chondrodysplasia punctate (RCDP) type 1 
Patients who have Refsum’s disease must cut phytanic acid from their diet (present in dairy 
products, ruminant animal fats and meats), reducing its concentration in plasma and some of its 
symptoms quite drastically [160]. Peroxisomal acyl-CoA oxidase deficiency like Refsum’s 
disease is a recessive genetic disorder, which is detectable by the accumulation of very long-
chain fatty acids (26 carbon atoms) in plasma [162]. 
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1.2.5.2 NEFA measurements in saliva 
Saliva glands are located in the oral cavity with saliva consisting of proteins, glycoproteins, 
lipids and inorganic ions, whose composition is affected by the diet of the individual [163, 164]. 
With neutral lipids (cholesterol, cholesterol esters, tri-, di- and mono-glycerides and NEFA) 
constituting 70-95 % of the total lipids, having NEFA (C12 to C22) as at least 10 % of that 
contribution [165, 166]. Recently using gas chromatography–mass spectrometry in resting saliva, 
the 4 main predominant NEFAs were identified as palmitic, oleic, linoleic and stearic acids with 
the concentrations ranging from 20 to 60 M [167, 168]. At the pH of saliva, NEFA is in its 
undissociated form so it is perceived as an irritant [169]. Oleic acid is used in studies due to its 
resistance to oxidation, low cost and high concentration in the human diet [170]. 
Humans can detect short, medium and long chain NEFAs via oral chemosensory detection [167, 
171].  NEFA can act as a signal for the presence of fat in the oral cavity and reflect the fatty acid 
composition in the diet, therefore the analysis of salivary NEFA may provide an objective and 
non-invasive method for the assessment of dietary fat intake in individuals [168]. Also in 
rodents, fat detection can be measured from the in-mouth release and detection of NEFA [172]. 
However the surface active properties of NEFA lead to desorption of interfacial properties and 
destabilization of emulsions, due to the favoured droplet coalescence [169].  
In diseases such as cystic fibrosis and Sjögren’s syndrome, there are also elevated NEFA levels 
in the patients saliva making NEFA an important biomarker for the disease diagnosis of these 
[163]. Cystic fibrosis is a hereditary disease in which the transmembrane regulator protein is 
affected, in this disease there are reduced levels of docosahexaenoic acid (C22:6) and increased 
levels of oleic acid [31]. Increasing the amount of docosahexaenoic acid in the diet has shown to 
improve the condition in some work [173]. In patients with multiple sclerosis, fatty acid 
supplements are used for treatment of symptoms, detection of NEFA would help in formulation 
of fatty acid supplements [36]. Increase in NEFA levels has also been found in patients with 
schizophrenia, as there are changes in metabolism [38]. 
However, there are three different types of salivary glands (submandibular, sublingual and 
parotid), each differing in the amount of NEFA they produce, further work is needed in this area, 
if an oral sensor was to be developed. 
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1.2.5.3 NEFA detection in animals 
Quantitation of NEFA in plasma and serum can be used to assess and monitor nutritional status 
in transitional cows (who are going through rapid foetal development, parturition and milk 
production) [174]. A negative energy balance (NEB) occurs in transitional dairy cows because of 
[175, 176]: 
 increased energy demands at parturition 
 decreased dry matter intake (DMI) shortly before parturition 
 lagging DMI compared with energy demands due to production of milk 
NEB causes increased circulation of NEFA and is positively associated with increased incidence 
of several postpartum diseases such as fatty liver, ketosis, hepatic lipidosis, metritis, retained 
placentas and displaced abomasums [175, 177-179]. 
Desirable NEFA concentrations in cow plasma are ~325 M. Above 400 M means there is a 
NEB along with subsequent intensive lipomobilization and NEFA serum concentrations above 
700 M are associated with ketosis [179-181]. In dairy cows, serum NEFA concentrations higher 
than 720 M has a reduced risk of pregnancy and milk production because of the direct 
physiological relationship between NEFA concentration and NEB [177]. During late pregnancy, 
there is an increased demand of glucose which leads to mobilization of lipid reservoir and 
increasing NEFA levels, plus there is higher NEFA concentration found in the plasma of twin 
bearing animals than there is a single foetus [182]. 
Household pets, such as cats and dogs can develop either type 1 or T2D, NEFA levels could be 
monitored here. In insulin-resistant horses there are also increased NEFA levels [183]. Normal 
NEFA concentrations are ~46 mol/L in healthy adult horses and ~100 mol/L in obese ones 
[184]. Lately a study of NEFA levels have also been done in camels [185]. 
Representative animal models are used to help in diabetes research for humans. The chosen 
animals for these controlled conditions are rats, mice, transgenic mice, desert gerbils, guinea 
pigs, sheep and pigs, because of their similar embryology, anatomy, physiology and 
pharmacology to humans [186-189]. It is best to use more than 1 model as this shows the variety 
in human diabetic patients [187]. These animals do not exactly develop diabetes but develop 
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conditions that would equate to human diabetes by exploration [188]. The analysis of the NEFA 
levels of these animal models would give biochemical and molecular biological mechanisms of 
the pathophysiology of disease. 
There are several blood variables (including glucose and NEFA) that are increased by 
transporting bulls from one area to another, due to stress [190, 191]. NEFA parameters have been 
measured in bulls that are going to slaughter houses and to genetic testing centres. Increase in 
NEFA concentrations were found in both types of transport. This is parallel to the increase in 
NEFA found in humans under stress discussed earlier [73, 74]. 
 
1.2.6 Conclusion 
In conclusion to part 1 of the literature review regarding NEFA itself, multiple interesting points 
have been highlighted. Firstly there has been no electrochemical NEFA biosensor ever 
developed for NEFA detection in human blood or blood in mammals. The current way of 
detecting NEFA in humans and mammals relies on expensive assays, which are beneficial for 
mass throughput only. This would not be needed for individual patient NEFA values. 
The importance of NEFA for T2D studies has been mentioned at length here and its evidence is 
also present in numerous literature regarding energy metabolism studies. The measurement of 
NEFA is useful in diseases/disorders other than T2D, such as Refsum’s disease, cystic fibrosis 
and Sjögren’s syndrome. The NEFA value in saliva has also been significant as a biomarker in 
some of these conditions, however due to the complexity of the secretions from the three salivary 
glands it has never been taken forward. 
NEFA has been detected in many energy metabolism studies in animals. With most of the recent 
publications of NEFA being in this sector, it gives another incentive to develop a sensor for 
blood NEFA measurements. 
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2 Biomarkers and Biosensors – Literature review part 2 
2.1.1 Biomarkers for energy metabolism 
Biomarkers are induced variations within cellular or biochemical mechanisms, processes, 
structures, or functions, that are quantifiable in a biological system or sample [192]. The 
International Programme on Chemical Safety (IPSC) of the World Health Organisation (WHO) 
has recognized three types of biomarkers; exposure, effect or susceptibility. Biomarkers are 
subjectively analyzed and evaluated as an indicator of normal biological/pathogenic process, or 
pharmacological reaction to therapeutic intervention by drugs or therapy [193].  
 
Glucose, glycosylated haemoglobin (HbA1c), lactate, cholesterol, creatinine, urea and retinol 
binding protein 4 (RBP4) are clinically important analytes and can be used as energy metabolism 
biomarkers. Each biomarkers relevance will be discussed in further detail below. 
The sweet taste of a diabetic patients urine as a biomarker for diabetes was recorded in the first 
century B.C. by Indian physicians in the Ayurveda scriptures of ancient Indian medicine, 
reported in Sanskrit [194]. Since then it has been noted that the proper absorption of glucose is 
biologically essential; diabetes can be caused by the poor absorption of glucose [195]. Currently 
the detection of glucose in blood is medically central for the diagnosis and management of 
diabetes as T2D is characterized by elevated glucose levels [196]. For this reason there have 
been multiple biosensors developed for glucose, with enzyme based biosensors being the main 
focus of biosensor research [197]. 
HbA1c is well known as a key diabetes marker protein and is the gold standard procedure for 
monitoring long-term glycemic control clinically in diabetics [198-200]. HbA1c is the major 
form of all glycohaemoglobin species in human blood and is defined as the stable adduct of 
glucose and the N-terminal amino group of the β-chain of HbA0 [N-(1-
deoxyfructosyl)haemoglobin] [201]. It is haemoglobin that has been irreversibly modified by 
addition of glucose through a slow, non-enzymatic process and the rate of its formation is 
directly proportional to the ambient glucose concentrations [193, 202]. HbA1c gives the mean 
glycemia over the preceding 2-3 months [8, 203]. It is also used by quality assurance programs to 
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assess the quality of diabetes care. HbA1c can be measured at any time of the day regardless of 
the duration of fasting or the content of the previous meal.  
The optimal therapy requires carefully validated, method-independent therapeutic target values 
for the glycohaemoglobin levels of patients with diabetes, lowering the long-term risk of late 
complications (e.g. retinopathy, nephropathy and neuropathy) and the short-term risk of life-
threatening hypoglycaemia [200, 201].  
The measurement of L-lactate is helpful in monitoring respiratory insufficiency, heart failure, 
metabolic syndrome, diabetes, tissue injuries and thrombosis [204]. The levels of lactate are also 
linked to status of anaerobic metabolism associated with muscle contraction and indicates 
oxygen supply [205]. 
Creatinine is used as a biomarker for renal and muscular dysfunctions [204]. It is a by-product of 
muscle metabolism and remains in a steady state by renal elimination [206]. 
High cholesterol build up in blood serum is strongly linked with many diseases, including 
coronary heart disease, arteriosclerosis, myocardial infarction, brain/cerebral thrombosis, lipid 
metabolism dysfunction, hypertension, hyperthyroidism and anaemia [207-210]. 
Indirect markers of mitochondrial function can also be abnormal in mitochondrial dysfunction 
[96].  Mitochondrial dysfunction can result in secondary urea cycle dysfunction and an elevation 
in ammonia levels, as the urea cycle is partially located in the mitochondria. Urea determination 
is used to study the proper functioning of the kidney, as progressive kidney function results in 
uraemia [211]. 
RBP4, a serum protein, facilitates the transport of retinol through the circulation to peripheral 
tissues [212]. It has been linked to obesity induced insulin resistance and T2D [213-215]. Its 
concentration in serum can be used to identify cardiovascular risk factors, including fatty liver 
disease. 
Table 2-1 lists the biomarkers and their relevant concentration in blood. Of course these 
concentrations vary on age, gender, disease, diet, exercise and disease etc., so fluctuations are 
possible. But typical ranges are listed here. 
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Table 2-1: The normal and abnormal blood concentrations of each energy metabolism biomarker studied. 
Biomarker 
Normal 
concentration 
Abnormal 
concentration 
Reference 
Glucose 5 mM 7 mM [216, 217] 
HbA1c ~ 5 % ≥ 6.5 % [218-220] 
Lactate 0.6 -2.0 mM 20 – 30 mM [205, 216] 
Cholesterol 11.1 mM 13.3 mM [221] 
Creatinine 53 – 115 M ~ 700 M [222] 
Urea 2.6 – 6.7 mM ~ 20 mM [211, 222] 
RBP4 ~ 30 M ~ 100 M [219, 222-224] 
 
2.1.2 Biosensor Development 
Biosensors are analytical devices which can convert a biological response into a measurable and 
processable signal [9]. Biosensors are selective biological systems (enzymes, antibodies, 
organelles, cells) combined with a transducer (thermistor, potentiometric and amperiometric 
electrode, piezoelectric and optical receivers) which generate on-line information from the 
investigated environment [225].  
The systematic depiction of a biosensor ought to have five features [226]; 
1. detecting/ measuring factor 
2. working principle of the transducer 
3. physical and chemical:biochemical representation 
4. appliance 
5. technology and materials for sensor fabrication. 
 
2.1.3 Glucose biosensors 
From all glucose biosensors, the enzyme-based electrochemical biosensors have been the major 
focus of biosensor research [197]. This can be due to their simplicity of use, moderately low cost 
and high sensitivity. Enzymes in enzyme electrodes catalyse redox reactions, during which they 
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give or take electrons (e
-’s) [7]. The transfer of e-’s can produce current or voltage that is 
concentration-dependent; this can be quantified using electrodes.  
The first generation of glucose biosensors (Figure 2-1) had glucose oxidase (GOx) as the enzyme 
in the biosensor (known as the ‘enzyme electrode’) in 1962 by Clark and Lyons [227]. In which 
the electrochemical reactions were: 
      GOx 
D-glucose + O2 + H2O  D-gluconic acid + H2O2      (1) 
H2O2 → 2H
+
 + O2 + 2e
−
         (2) 
 
 
Figure 2-1: Clarke-type O2 electrode illustration [204]. 
It made use of O2 as an e
-
 mediator from GOx to the surface of electrode. GOx reduces O2 into 
H2O2 with glucose present [228]. The concentration of glucose is proportional to the rate of O2 
reduced. This is detected by measuring the increase of H2O2 concentration or decrease of O2 
concentration. This generation of glucose sensors suffered from O2 dependence and intervention 
by redox-active species. 
Figure 2-2 illustrates the general construction of the second generation of glucose sensors. These 
use artificial mediators to overcome O2 limitation under low O2 pressure [228]. The e
-
 mediators 
facilitate the e
-
 transfer by fast shuttling of e
-’s between the enzyme and electrode.  The most 
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popular e
-
 mediators are ferro/ferricyanide, hydroquinone, ferrocene and various redox organic 
dyes. Having other redox-active species (e.g. O2) will compete with the mediators. 
 
Figure 2-2: Schematic diagram of the second generation enzyme glucose sensors [228]. 
 
The third generation glucose sensors use direct e
-
 transfer [228]. Here the e
-’s are directly 
transferred between the enzyme and electrode. If the electrode and the active redox sites of the 
enzyme were electrically wired, the direct e
-
 transfer would convert the enzymatic recognition 
events of glucose to an amperometric signal, in effect not considering the concentration of co-
substrates, for instance those of O2 or redox mediators. The best plus point of this design is the 
successful elimination of potential interferences. 
 
In the 1980s the development of self-monitoring of blood glucose with a single drop of blood 
became possible [229]. Over 90 % of the glucose sensor market is being shared by the 
companies LifeScan, Roche Diagnostics, Abbott and Bayer [230]. Table 2-2 lists the products 
and their relevant information. All these rely on the finger-prick method of glucose detection. 
Table 2-2: Leaders in glucose home sensing kits. 
Company 
Trade name of 
product 
Mediator used 
Sample 
volume (L) 
Reference 
Abbott 
Precision Ferrocene 0.6 [231, 232] 
FreeStyle Osmium “wire” 0.3 [233] 
Bayer Elite Ferricyanide 2.0 [234] 
LifeScan 
SureStep 
Ferricyanide 
5.0 [235] 
One Touch Ultra 1.0 [236] 
Roche Diagnostics Accu-Check Ferricyanide 1.5 [237] 
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American Diabetes Association, the FDA and the National Institutes of Health did issue a 
collaborated declaration in 1986, regarding the self-monitoring of blood glucose for [7]: 
 diabetes causing pregnancy to be problematic; 
 people having severe ketosis or hypoglycaemia; 
 people prone to hypoglycaemia; 
 people on intensive treatment programmes; 
 people having abnormal renal glucose thresholds. 
 
Nowadays self-monitoring of glucose is routine in patients of T2D, as this helps them manage 
their diabetes and improve their lifestyle. Self-monitoring of plasma glucose is recommended by 
the National Institute for Health and Care Excellence (NICE) for the following individuals [238]: 
 on insulin treatment  
 on oral glucose lowering medications (so information on hypoglycaemia can be obtained)  
 who need to assess changes in glucose control subsequent to medications and lifestyle 
changes  
 who monitor changes during illness  
 who need to ensure safety during activities (such as driving) 
There have been many review papers on the home blood glucose sensors [239, 240]. There are 
over 6000 peer reviewed articles on electrochemical glucose assays and sensors [241]. Along 
with many papers comparing the accuracy of one commercial meter to others [242-245]. This is 
a well established field in the biosensor market. The advantages and disadvantages of self-
monitoring are illustrated in Figure 2-3 below. The same advantages and disadvantages would 
apply for NEFA finger-prick sensing too. 
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Figure 2-3: Advantages and disadvantages of home based glucose sensors from the patients perspective [246]. 
 
2.1.4 Advantages of electrochemical biosensors 
Electrochemical biosensors are robust, easily miniaturized and have outstanding detection limits 
compared to optical biosensors. Electrochemical biosensors take low analyte volumes, and can 
work in turbid biofluids which have optically absorbing and fluorescing components [9]. They 
are greatly sensitive and selective, portable, giving a fast response, specific, and low cost. They 
can be used for a number clinical applications, from ‘alternative-site’ testing (e.g. physician’s 
office), emergency-room screening, bedside monitoring, or home self-testing [207, 247]. There 
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are some disadvantages of electrochemical sensors, including: the sample could have 
electrochemically active interferences, it could be weak in relation to long-term reliability and 
have complicated e
-
 transfer pathways. 
 
2.1.5 Electrochemistry 
Electrochemistry deals with nature and properties of substances containing charged particles 
(ions) and the relationship between chemical reactions and electrical currents [248]. 
Analytical applications of current-voltage relationships forms the foundation of the wide range of 
voltammetric methods [249]. In this study Cyclic Voltammetry (CV), Linear Sweep 
Voltammetry (LSV) and Chronoamperometry (CA) were selected. All are accomplished using a 
three-electrode arrangement. Electrochemical sensing usually requires a reference electrode, a 
counter or auxiliary electrode plus a working electrode, also known as the sensing or redox 
electrode [9]. The reference electrode is kept at a distance from the reaction site in order to 
maintain a known and stable potential with which the current produced on the working electrode 
is compared. The working electrode serves as the transduction element in the biochemical 
reaction, while the counter electrode (non-reactive high surface area) establishes a connection to 
the electrolytic solution so that a current can be applied on the working electrode (well defined 
area). The electrodes ought to be both conductive and chemically stable. A typical 
electrochemical cell can be seen in Figure 2-4. The electrodes would be connected to a 
potentiostat. 
 
Figure 2-4: Typical electrochemical cell, with standard three-electrode set-up comprising of working, counter and 
reference electrodes [204]. 
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2.1.5.1 Cyclic voltammetry (CV)  
CV is an incredibly handy and resourceful electrochemical technique in the characterization of 
electroactive species [250]. It collects valuable information in relation to the stability of the 
oxidation states and the rate of e
-
 transfer from the electrode and the analyte. Current 
measurement as a function of the applied potential gives information about the analyte. The 
current response against a variety of potentials is measured, beginning at an initial value and 
changing the potential in a linear way up to a limiting value. At this limiting potential value the 
course of the potential scan is reversed and the same potential range is run in the reverse 
direction. The species that were oxidized in the forward scan can be reduced in the backward 
scan. CV is useful in the elucidation of reaction mechanism, especially with identification of 
intermediates [249]. 
 
2.1.5.2 Linear sweep voltammetry (LSV) 
In LSV the potential scan is done in one direction only, and stopped at a chosen potential [251]. 
The direction of the scan can be either positive or negative. On reaching a potential where the 
electrode reaction begins, the current produced will rise. Nonetheless, a concentration gradient is 
created and consumption of electroactive species results in continuing to sweep the potential, 
from a certain value just before the maximum value of the current (peak current), the supply of 
electroactive species fall. Due to depletion the current decays. 
 
2.1.5.3 Chronoamperometry (CA) 
This is the study of variation of the current response with time. CA is a technique extensively 
engaged to establish kinetic rate constants in reactions which have e
-
 transfer of their surface-
confined redox couples [252]. The Cottrell equation is what the results of the CA are derived 
from, this demonstrates the current-time dependence for linear diffusion control [253]: 
i = nFACD
½-½t-½ 
In which: i = current 
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n = number of e
-’s transferred/molecule  
F = Faraday constant (96,500 C mol
-1
) 
A = area of the electrode (cm
2
) 
D = diffusion coefficient (cm
2
s
-1
) 
C = concentration (mol cm
-3
)  
t = time (seconds) 
Subsequently this shows that following the conditions listed the relationship among the current 
and the 1/square root of time is a linear one.  
 
2.1.6 H2O2 produced as a by-product  
Just as the quantification of glucose, cholesterol and lactate can be achieved via the 
electrochemical detection of the enzymatically liberated H2O2 (Figure 2-5), in principle so can 
the quantification of NEFA [209, 254]. H2O2 as a by-product of enzymatic reactions catalysed by 
the oxidase enzymes renders it an important analyte in the biosensor field [255-257]. H2O2 
serves as an electroactive reporter molecule in the indirect detection of non-electroactive 
biomolecules, e.g. glucose, glutamate and acetylcholine [258]. Other classical biochemical 
reactions which produce H2O2 as a side product are catalyzed by the enzymes alcohol oxidase 
(AlOx), urate oxidase (UOx), D-amino acid oxidase (DAAO), glutamate oxidase (GlOx), lysine 
oxidase (LyOx), oxalate oxidase (OxaOx), and so on [259]. 
The enzymatic detection of NEFA relies on the oxidation of acylated NEFA, e.g. palmitoyl 
coenzyme A (PA-CoA) or oleoyl coenzyme A (OA-CoA) by the enzyme acyl-Coenzyme A 
oxidase (ACOD), producing H2O2 which is then quantifiable. 
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Figure 2-5: Clinically important reactions producing H2O2 as a by-product. 
H2O2 is a simple compound. The dissociation energy of the O-O bond in H2O2 is 35 kcal mol
-1
 
[260]. The detection of H2O2 is important for pharmaceutical, clinical, environmental, mining, 
textile and food manufacturing applications [259, 261, 262]. Accurate and reliable detection of 
H2O2 has been thoroughly investigated using chromatography, titrimetry, chemiluminescence 
and electrochemistry [261, 262]. Over other detection methods of H2O2, electrochemical analysis 
offers improved sensitivity, an extended dynamic range and a rapid response time [257]. 
Amperometric H2O2 detection possesses good temporal resolution for rapid and real-time 
measurements, allowing continuous recording of the oxidation/reduction currents as a function of 
time without severe contamination by capacitive current [263]. 
2.1.7 H2O2 oxidation and reduction 
Electrochemically H2O2 can be directly oxidized or reduced at ordinary solid electrodes [259]. 
Both these process can be electrocatalyzed by carbon nano-tubes (CNT). 
The oxidation of H2O2 to O2 occurs by HO2 radicals and without chain reactions, the process is 
in two stages in aqueous solutions [264]: 
H2O2 – e
-
  HO2 + H
+
, Go = 49 kcal,   
HO2 – e
-
  H+ + O2, G
o
 = -13 kcal,     
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i.e., for the complete reaction H2O2  O2 + 2H
+
, Go = 36 kcal. 
H2O2 decomposition is presumed to be pseudo-first-order kinetics [265]: 
- dCH2O2 / dt = kd × CH2O2 
kd represents an apparent kinetic constant (including many parameters e.g. temperature, catalyst 
concentration and pH). 
The general scheme of oxygen reduction is shown in Figure 2-6. The direct four electron 
reduction to water (or OH
-
) is k1, k2 is the two electron reduction to H2O2 (or OH2
-
), k-2 is the 
oxidation of H2O2 (or HO2
-
) to O2, k3 is the electrochemical reduction to H2O or (OH
-
) of H2O2, 
k4 is the catalytic decomposition of H2O2 (or HO2
-
) to the reducible O2, k5 is the desorption of the 
adsorbed H2O2 (or HO2
-
) and finally k6 is the adsorption of H2O2 (or HO2
-
) [266].  The * term is 
the vicinity of the disc electrode, as the rotating ring disk assembly was not used in this work, 
therefore these species are not relevant here.  
 
Figure 2-6: General scheme of oxygen reduction [266]. 
The adsorbed peroxides desorption depends on the electrolyte plus the impurities and on the 
electronic and morphological properties of the electrode too [267]. 
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2.1.8 Conclusion 
The second half of the literature review focussed on biomarkers of energy metabolism, 
biosensors, glucose biosensor development and electrochemistry involving H2O2 detection. 
There are multiple energy metabolism biomarkers (as discussed previously) and biosensors have 
been developed subsequently to analyse these concentrations in patients. The glucose biosensor 
is by far the largest market in energy metabolism biosensors. These sensors do involve the 
electrochemical detection of H2O2 from an enzymatic reaction. The same principle would be 
used for NEFA detection from the enzymes and then from in blood. An electrochemical 
biosensor for detecting NEFA levels would be useful in many energy metabolism fields. This 
draws on the conclusions found after the first part of the literature review. 
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2.2 Aims and objectives 
Aim 
 To develop an electrochemical based NEFA biosensor for patients with T2D or energy 
metabolism conditions. The biosensor will measure NEFA concentrations in blood and 
will be useful for the future development of personalised intervention programmes for the 
treatment and management of the disease. 
 To collate useful information regarding NEFA in literature and see where else a NEFA 
sensor would be beneficial. 
 
Objectives 
 To use optical methods (such as those used by the companies, Wako Diagnostics and 
Roche Applied Science) for NEFA detection as feasibility study, and develop 
electrochemical methods for measuring NEFA concentrations in blood. 
 To develop enzyme electrodes for NEFA sensors and improve its sensitivity and 
measurement limitation by enhancing signal generation and improving the electrode 
surface properties. The enzyme electrode will be fabricated by immobilizing enzymes to 
the screen printed carbon electrode using polymers. The interaction and electron transfer 
between the enzymes and the electrode will be studied. There will be optimization and 
modification of materials on the surface property of the electrode.  
 To investigate the interference with multiple analytes on the electrode. This is needed to 
understand the interference of mixed analytes on the sensor, and whether this would 
affect the sensors sensitivity and selectivity. 
 
The initial work in solution with the enzyme ACOD and the substrates OA-CoA/PA-CoA is 
shown in Chapter 3, followed by the work on enzyme electrode fabrication for NEFA (oleic 
acid) detection in Chapter 4. Both these chapters include sections on interference using these un-
fabricated and fabricated electrodes. Chapter 5 covers detection of NEFA in human blood using 
the fabricated enzyme electrodes. The overall conclusions and recommendations of future work 
are given in Chapter 6. The appendix (Chapter 7) contains data/explanations that support the 
work in the main body of the thesis. This section has been referred to whenever necessary. 
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3 NEFA detection in solution using screen printed electrodes (SPE’s) 
3.1 Introduction 
The oxidation of NEFA requires an oxidase enzyme Acyl-Coenzyme A oxidase (ACOD). In 
literature there are over 200 dehydrogenases enzymes and 100 oxidases [268]. Many of which 
specifically catalyse the reactions of clinically important analytes (e.g. glucose, lactate, 
cholesterol, amino acids, urate, pyruvate, glutamate and alcohol hydroxybutyrate) to generate 
products that are electrochemically detectable (e.g. reduced nicotinamide adenine dinucleotide 
(NADH) and H2O2). 
Glucose oxidase (GOx) is the most widely used of the class of oxidoreductases enzymes [269]. 
First generation glucose sensors monitored glucose concentrations by monitoring H2O2 
evolution. This was from the reaction of GOx converting glucose to glucolactone and oxygen to 
H2O2. Applying this principle to the NEFA sensor would replace glucose with NEFA (as the 
substrate) and GOx with ACOD (as the enzyme) and then monitor the H2O2 evolution from this 
reaction. This would make a first generation NEFA sensor.  
ACOD is a flavoprotein, that donates its electrons directly, catalysing the stoichiometric 
conversion of acyl-Coenzyme A and O2 into enoyl-Coenzyme A and H2O2 [162, 270]. ACOD 
oxidises acyl-CoA’s with 4 to 20 carbon atoms, it is an octamer with a molecular weight of 
~600,000 approximately, with its isoelectric point being 5.5 [270]. ACOD catalyses the first and 
rate-determining step of fatty acid -oxidation [271, 272]. The activity of ACOD is stimulated by 
flavin adenine dinucleotide (FAD), a redox active prosthetic group of flavoenzyme that catalyses 
important biological redox reactions [273, 274]. There are 8 mol of FAD per mol of ACOD [270, 
272, 275]. ACOD has enoyl-CoA isomerase activity. Reduced flavin adenine dinucleotide 
(FADH2) is reoxidised by molecular oxygen, as shown in Figure 3-1. 
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Figure 3-1: ACOD catalysed reaction of acylated NEFAs [272, 275]. 
The two step enzymatic reaction is shown in Scheme 1. In the first step NEFA reacts with 
Coenzyme A (CoA) and adenosine triphosphate (ATP) with the enzyme acyl-Coenzyme A 
synthetase (ACS) to produce Acyl-Coenzyme A, which then reacts with the enzyme ACOD to 
produce H2O2, which is of interest in this work. 
 
Scheme 1: Reaction scheme of the enzymatic method for H2O2 production from NEFA. 
In step 1 of scheme 1, palmitoyl Coenzyme A (PA-CoA) would be the product if palmitic acid 
(saturated carbon 16 fatty acid chain) was the NEFA or oleoyl Coenzyme A (OA-CoA) would be 
the product if oleic acid (carbon 18 with 1 double bond) was used. 
Palmitic acid and oleic acid represent the major species present in human serum and therefore 
are some of the principal molecules to which -cells might be exposed to in vivo [115]. For this 
reason they are also used as standards for the commercial kits on the market. Therefore palmitic 
acid/oleic acid (or their acylated forms, PA-CoA/OA-CoA) would be good reference NEFAs for 
this investigation. The H2O2 produced after step 2 was to be detected electrochemically using 
different screen printed electrodes (SPE’s). 
Requirements for electrodes in electrochemistry are on the basis of having good electrode 
material with stability over a long-time, low residual current and use over a wide potential range 
[276]. Carbon electrodes have all these 3 requirements along with a rich surface chemistry. 
Carbon oxidation has slow kinetics resulting in a wide useful potential range, particularly in the 
41 
 
anodic direction. Carbon based electrodes have congruity for many applications in 
electroanalytical chemistry, so were chosen as the initial electrode in this work. Single use screen 
printed electrodes (SPE’s) eliminate problems such as loss of response caused by electrode 
fouling and enzyme denaturization [276]. Their surface can be easily modified, they are easy to 
use and cost-effective [256]. 
Screen-printing can produce electrodes as those shown in Figure 3-2. These are produced by 
printing patterns using a stencil and building-up each layer onto the plastic or ceramic sheet 
substrate. Each strip consists of a working electrode coated with the necessary reagents such as 
the enzyme, mediator, linking and binding agents, the counter electrode and the reference 
electrode [230].  
 
Figure 3-2: Sheet of 16 screen printed carbon electrodes. 
 
3.2 Experimental 
3.2.1 Materials 
H2O2 33 % 
w
/w in water was purchased from VWR (Leicestershire). Stock solutions were made 
using distilled water as the diluent. 
Disodium hydrogen phosphate (Na2HPO4) and sodium dihydrogen phosphate dehydrate 
(NaH2PO4), was purchased from Sigma Aldrich (Dorset, UK). 0.1 M phosphate buffer (pH 7.4) 
Reference 
electrode 
Working 
electrode 
Counter 
electrode 
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was prepared from stock solutions of 1 M Na2HPO4 and NaH2PO4. The pH was checked by 
using a pH meter. 
PA-CoA and OA-CoA were purchased from Sigma Aldrich. Stock solution of 10 mM for each 
was made by diluting in 0.1 M phosphate buffer (pH 7.4). ACOD was purchased from Wako 
Japan at 100 Units, CAS # 61116-22-1 (Neuss, Germany). Each run contained 3 U/mL ACOD. 
This concentration was selected as it was the concentration stated in the Wako kit in the optical 
method. 
 
The following SPE’s were purchased from DropSens (Oviedo, Spain): 
• Cobalt phthalocyanine (CoPc) SPE – model DRP-410. The working electrode (WE) is 
CoPc on carbon.  
• Carbon (C) SPE – model DRP-C110. The WE is carbon.  
• Single wall carbon nanotube (SWCNT) SPE – model DRP-110SWCNT. The WE 
consists of carboxyl functionalised SWCNT. 
All the electrodes have a flat surface. The electrodes have a working electrode diameter of 0.40 
cm and an area of 0.13 cm
2
. For all 3 DropSens electrodes, the reference electrode is silver/silver 
ion (Ag) and the counter electrode is carbon. The dimensions of all the electrodes are 3.40 x 1.00 
x 0.05 cm (Length x Width x Height) respectively. These disposable electrodes were used as 
purchased with no pre-treatment required. 
All interference work was done using C-SPE (DRP-C110). The ACOD was from the Roche kit, 
30 L was used per run. The concentration of ACOD in the commercial kit is not stated. Urea 
and bovine serum albumin (BSA) was purchased from Sigma Aldrich (Dorset, UK). Uric acid 
and ascorbic acid were purchased from Alfa Aesar (Heysham, Lancashire). Glucose was 
purchased from Fluka BioChemika (Dorset, UK). Stock solutions for each of these were made by 
diluting the relevant mass in 0.1 M phosphate buffer (pH 7.4). Acetaminophen (paracetamol) and 
aspirin were purchased from the pharmacy. The stock solutions were made after the active 
ingredient was calculated. The tablet was crushed, then dissolved in 0.1 M phosphate buffer (pH 
7.4), then sonicated for 40 minutes. The percentage of interference was calculated by using 0.20 
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mM PA-CoA as a reference (with ACOD) and spiking this with the relative amount of each 
respective interference that is present in serum/plasma. 
 
3.2.2 Electrochemical measurements 
Electrochemical measurements were run on the Autolabs (PGSTAT101 and PGSTAT302) with 
NOVA 1.8 as the software package installed. Cyclic Voltammetry (CV) was done using a scan 
rate of either 5 mV s
-1
, 50 mV s
-1
, 100 mV s
-1 
or 500 mV s
-1
. The potential range investigated 
was from -800 mV to 500 mV or up to 600, 800, 1000, 1200, 1400 and 1600 mV. Linear Sweep 
Voltammetry (LSV) was done using a scan rate of 1 mV s
-1
. The potential range investigated was 
from 0 mV to 600 mV. Chronoamperometry (CA) was done at a set potential of 500 mV with a 
step potential of 0.25 seconds (s) and duration of 1500 s. 500 mV was the chosen potential 
because at this potential there was substantial oxidation of H2O2, which was seen from the LSV.  
All CA for interference work was done at a set potential of 500 mV with a step potential of 0.25 
s and duration of 500 s. All CA calibration graphs in the study are shown at 500 s. This time was 
chosen for all the graphs to keep the representation of time consistent. 
The electrolyte used throughout the work was 0.1 M phosphate buffer (pH 7.4 - same as blood).  
All electrochemical experiments were done at room temperature, in at least duplicates wherever 
there are error bars. Error bars were worked out based on the average, the positive error was the 
most positive result minus the average, the negative error was the average minus the most 
negative result. 
The experimental set-up is shown in Figure 3-3. The SPE was sealed in the cell shown by the 
four screws. This prevented solution leakage. The total volume of solution in the cell was 100 
L. 
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Figure 3-3: Experimental set-up for electrochemical experiments. 
 
Working 
electrode 
Counter 
electrode 
Reference 
electrode 
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3.3 PA-CoA/OA-CoA detection electrochemically in solution 
3.3.1 Detection using carbon screen printed electrode 
Initially the LSV of different concentrations of H2O2 were detected on a C-SPE (Figure 3-4 and 
Figure 3-5). The sensitivity of the C-SPE towards H2O2 was determined to be 0.70 A/mM at 
500 mV. This would then be compared later with the data obtained from the acylated NEFAs 
investigated. The same concentration range of 0.00 mM to 3.00 mM will be investigated for 
acylated NEFA as this covers the NEFA range found in human blood. Testing the electrode with 
actual H2O2 proved that the electrode can be used for various concentrations of H2O2, and 
produce a linear response (R
2
 of 0.99). These C-SPE’s are designed and sold as a detection tool 
for low concentrations of H2O2 detection. The lowest concentration investigated with H2O2 was 
0.10 mM. 
 
Figure 3-4: LSV for various concentrations of H2O2 measured at a C-SPE in 0.1 M phosphate buffer pH 7.4, scan rate 1 
mV s-1. 
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Figure 3-5: Calibration graph at 500 mV. 
 
Figure 3-6 shows the log j (flux – which is the current produced divided by the surface area of 
the WE) vs. log H2O2 plots for different potentials from 400 to 600 mV (vs. Ag). A slope of 0.95 
to 1.03 was obtained for the entire log j (flux) vs. log H2O2 range. This result indicates that the 
reaction is first-order with respect to [H2O2] as the slope is ~ 1. The only variant that is changing 
in this graph is the concentration of H2O2. Calibration graphs can be made from the potentials of 
400 to 600 mV, as this is the region in which the oxidation of H2O2 takes place on a C-SPE. The 
R
2
 value was around 0.99 for each potential. This proves these electrodes are suitable for H2O2 
detection. 
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Figure 3-6: The relationship between log j and log H2O2 concentration on the C-SPE at various electrode potentials in 0.1 
M phosphate buffer pH 7.4. 
 
The current produced at the potential of the calibration graphs is due to the oxidation of H2O2. 
H2O2 has a very high overpotential for oxidation at the bare carbon surface (unmodified carbon 
electrode) [209, 269]. -47 mV is the formal potential for the oxidation of H2O2 at pH 7.4 in 
homogeneous solution. The current from the oxidation of H2O2 begins at ~300 mV. Applying 
this high voltage in a sensor the system may be susceptible to interference by other readily 
oxidizable compounds [277]. 
For an irreversible reaction (H2O2 oxidation) the kinetics has an important role [251]. A higher 
potential (overpotential) needs to be applied to overcome the activation barrier and allow the 
reaction to occur. The electrical current flowing through the electrode is proportional to the 
reaction rate and the electrode potential is proportional to the driving force [278]. The driving 
force for a chemical reaction is Go (standard free energy of the reaction). This driving force can 
be modified by changing the electrode potential because G = -nFE, where n is the number of 
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electrons, F is Faraday constant (charge on one mole of electrons, 96,484.6 coulombs) and E is 
the potential of the cell. For an oxidation reaction (the oxidation of H2O2), the driving force can 
be increased by applying a positive potential. Therefore all the calibration graphs for LSV in this 
study are at a chosen positive potential of 500 mV. All CA should also be done at 500 mV for 
consistency. 
Different concentrations of PA-CoA and OA-CoA were then detected using the techniques LSV 
and CA. These experiments were performed with enzymes and substrate in solution. These 
experiments are crucial as they demonstrate the possibility of H2O2 detection in solution from its 
enzymatic production from acylated NEFA.  
The LSV of PA-CoA is shown in Figure 3-7 (inset showing calibration graph at 500 mV), this 
graph shows H2O2 is detectable above the potential of 300 mV.  0.05 mM PA-CoA was also 
detected here, this low concentration also fitted into the general trend. The R
2
 value was over 
0.99 for 500 mV. With a sensitivity of ~1.13 A/mM PA-CoA at 500 mV. 
The sensitivity of PA-CoA detection was a lot higher than that of H2O2 detection (~1.13 A/mM 
vs. ~0.70 A/mM). This may be due to the decomposition of H2O2 which could be happening a 
lot more rapidly in H2O2 solution when compared to the H2O2 produced from PA-CoA oxidation. 
Decomposition of H2O2: 
2H2O2  2H2O + O2 
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Figure 3-7: LSV for various concentrations of PA-CoA measured at a C-SPE with ACOD in 0.1 M phosphate buffer pH 
7.4 , scan rate 1 mV s-1. Inset: calibration graph at a potential of 500 mV. 
 
Figure 3-8 shows the log j vs. log PA-CoA plots for different potentials from 400 to 600 mV (vs. 
Ag). A slope of values between that of 0.73 to 0.87 was obtained for the entire log j vs. log PA-
CoA range. This suggests a reaction order of approximately 1 with respect to PA-CoA 
concentration for the oxidation of H2O2. This value is not as close to 1 as expected because one 
enzymatic reaction needs to occur before H2O2 is produced and oxidised on the electrode 
surface. R
2
 value was above 0.97 for each potential. 
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Figure 3-8: The relationship between log j and log PA-CoA concentration at various electrode potentials in 0.1 M 
phosphate buffer pH 7.4. 
 
Figure 3-9 shows the CA at the set potential of 500 mV for concentrations of PA-CoA up to 3.00 
mM concentration. A calibration graph (Figure 3-10) was obtained from the current produced at 
500 s. Linear increase of current was observed with increasing concentrations of PA-CoA. The 
amount of H2O2 produced from the reaction is proportional to the amount of PA-CoA to begin 
with, as this is a 1:1 molar reaction. The sensitivity of the C-SPE towards PA-CoA detection in 
solution is 0.6326 A/mM.  
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Figure 3-9: Chronoamperometry at 500 mV of various PA-CoA concentrations on C-SPE in 0.1 M phosphate buffer pH 
7.4 with ACOD in solution. 
 
Figure 3-10: Calibration graph of current against PA-CoA concentration at 500 s. 
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The same CA was then done for the other acylated NEFA of interest OA-CoA, shown in Figure 
3-11 and Figure 3-12 (calibration graph). With a similar sensitivity of 0.6519 A/mM to that of 
PA-CoA. A bar chart showing the similarity of the current obtained from both acylated NEFAs is 
shown in Figure 3-13. This shows the current produced from the two acylated NEFAs is similar. 
The electrode is almost as sensitive to either of the two substrates. The slight difference may be 
due to error in experimentation, doing repeats and working out the standard deviation (SD) of 
error would help confirm this. 
Step two (in Scheme 1) of the enzymatic reaction of acylated NEFA oxidation in the presence of 
ACOD can happen with any acylated NEFA. Both these acylated NEFAs are of interest for 
NEFA sensor development. 
 
Figure 3-11: Chronoamperometry at 500 mV of various OA-CoA concentrations on C-SPE in 0.1 M phosphate buffer pH 
7.4 with ACOD in solution. 
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Figure 3-12: Calibration graph of current against OA-CoA concentration at 500 s. 
 
 
Figure 3-13: Bar chart comparing the current produced from the two different acylated NEFAs on SWCNT SPE. CA at 
500 mV, current taken at 500 s. 
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As stated earlier, the driving force can be increased by applying a positive potential, this is 
proven by the CV’s done at a scan rate of 100 mV s-1, shown in Figure 3-14. The concentration 
of 0.50 mM PA-CoA was used for the investigation. To determine the potential limit required to 
sufficiently oxidise the electrode surface for the H2O2 oxidation, the switching potential was 
varied from 0.6 to 1.6 V. The amplitude of the oxidation current increased as the potential limit 
increased. As in the higher the positive potential the more H2O2 oxidised. 
H2O2  2H
+
 + 2e
-
 + O2 
Table 3-1 shows the current produced for each scan rate (5, 50, 100 and 500 mV s
-1
) at the upper 
potential for the same concentration of 0.50 mM PA-CoA. Maximum sensitivity was observed 
using a potential of 1.6 V. However, having a very high positive potential may result in 
charcoalization of the electrode. The surface of carbon at 1.0 V can be deeply oxidized and 
create surface oxygen groups which contribute to more effective H2O2 oxidation [265].  For G
o
 
to be spontaneous at constant temperature and pressure it needs to be as negative as possible, 
therefore it is not ideal to go to such positive potentials.  
Now that it has been confirmed that the oxidation of H2O2 is feasible and detectable on a C-SPE, 
optimisation for best results in terms of linear detection range and sensitivity needs to be 
explored. For this reason other SPE’s (either incorporating carbon nanotubes (CNT) and/or 
catalysts such as cobalt) needed testing for H2O2 oxidation/production from the enzymatic 
reactions. These electrodes may detect the oxidation of H2O2 at lower potentials, reducing the 
overpotential and activation barrier required for reaction to take place. 
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Figure 3-14: CV of 0.50 mM PA-CoA and ACOD at scan rate of 100 mV s-1 using a C-SPE with increasing upper limit 
potential varying from 0.6 V to 1.6 V. 
Table 3-1: The current obtained for each scan rate for each upper potential for 0.50 mM PA-CoA. All data is background 
subtracted. Data given in 6 significant figures. 
Upper potential 
(V) 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 5 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 50 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 100 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 500 
mV s
-1
 
0.6 4.35790 14.4195 18.9118 35.0036 
0.8 8.06580 25.9156 33.8318 67.9018 
1.0 35.9253 76.5684 84.4731 113.922 
1.2 76.5690 147.949 168.457 211.579 
1.4 119.293 238.830 273.773 332.641 
1.6 80.8720 253.902 294.492 369.870 
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3.3.2 Detection using single wall carbon nanotube screen printed electrode 
CNT have been extensively used since they were discovered by Iijima in 1991 [279]. CNT in 
electrochemical measurements provide a large surface area and enhance electron transfer in 
reactions for a great number of molecules (such as GOx) and have the possibility of 
miniaturization for further development of electrochemical biosensors [280-282].  
The redox currents of inorganic, organic compounds/molecules, macrobiomolecules and 
biological cells can be improved by replacement of ordinary materials by CNT and reducing the 
redox overpotentials [209]. The next electrode investigated was the single wall carbon nanotube 
(SWCNT) SPE. Chronoamperometric results for PA-CoA are shown in Figure 3-15, with the 
corresponding calibration graph at 500 s in Figure 3-16. This gave a linear range up to 3.00 mM 
PA-CoA, with R
2
 of 0.9960 and a sensitivity of 0.7358 A/mM at 500 mV. With the SWCNT 
electrode, there should have been an increase in current as the surface area increased when 
compared to plain C-SPE (Figure 3-9). The amount of current produced and sensitivity remained 
similar. However there was still a high overpotential for the oxidation of H2O2.  
Chronoamperometric results for OA-CoA are shown in Figure 3-17, with the corresponding 
calibration graph in Figure 3-18, showing a linear range up to 3.00 mM of OA-CoA too, R
2 
of 
0.9960 and a sensitivity of 1.0725 A/mM, at the set potential of 500 mV.  
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Figure 3-15: CA at 500 mV of various PA-CoA concentrations on SWCNT SPE in 0.1 M phosphate buffer pH 7.4 with 
ACOD in solution. 
 
Figure 3-16: Calibration graph at 500 s. 
y = 0.7358x + 0.0386 
R² = 0.9960 
SD = 1.0780 
0.0
0.5
1.0
1.5
2.0
2.5
0.0 0.5 1.0 1.5 2.0 2.5 3.0
i 
/
A
 
PA-CoA concentration /mM 
58 
 
 
Figure 3-17: CA at 500 mV of various OA-CoA concentrations on SWCNT SPE in 0.1 M phosphate buffer pH 7.4 with 
ACOD in solution. 
 
Figure 3-18: Calibration graph at 500 s. 
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The LSV of PA-CoA using this electrode is shown in Figure 3-19 (with Figure 3-20 showing the 
calibration graph at 500 mV). The response was linear up to 3.00 mM PA-CoA. The R
2
 value 
was ~ 0.98, with a sensitivity of ~1.1 A/mM. 
 
Figure 3-19: LSV for various concentrations of PA-CoA measured at a SWCNT SPE with ACOD  in 0.1 M phosphate 
buffer pH 7.4 , scan rate 1 mV s-1.  
 
Figure 3-20: Calibration graph at 500 mV. 
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3.3.3 Detection using cobalt phthalocyanine screen printed electrode 
Another electrode commonly used to detect H2O2 chronoamperometrically is the cobalt 
phthalocyanine (CoPc) SPE. The CA results are shown in Figure 3-21 and Figure 3-22. The 
CoPc SPE gave a linear range up to 3.00 mM PA-CoA, with R
2 
of 0.99 and a sensitivity of 
1.1664 A/mM at 500 mV. This electrode gave the highest sensitivity and current. Due to its 
high catalytic activity, CoPc is the most sensitive material for detecting H2O2 [283]. 
 
Figure 3-21: CA at 500 mV of various PA-CoA concentrations on CoPc SPE in 0.1 M phosphate buffer pH 7.4 with 
ACOD in solution. 
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Figure 3-22: Calibration graph at 500 s. 
 
Metallophthalocyanines are extremely versatile materials, due to their macrocyclic nature 
(extended -system) they are capable of undergoing fast redox processes with minimal 
reorganizational energies and can also act as mediators in electron transfer processes involving 
many molecules [278]. Phthalocyanine electrodes act by lowering the overpotential of oxidation 
or reduction of the target molecules. Metallophthalocyanines act as catalysts in solution phase 
H2O2 electrochemical oxidation and reduction [283]. The catalytic activity is related to the 
central metal in the phthalocyanine, the frontier molecular orbitals of the reactant interact with 
the frontier orbitals situated on the metal centre, aiding the transfer of electron to and from the 
target molecule [284]. CoPc is a potent catalyst for H2O2 oxidation and reduction. In this study 
the CoPc SPE was shown to have reduced the activation energy and the reaction occurred faster, 
therefore H2O2 was oxidized at a lower potential (on CoPc SPE) compared to the C-SPE and 
SWCNT SPE. The reaction on CoPc electrodes can be written as follows: 
2Co3+/2+Pc  + H2O2    2Co
2+/+Pc  + 2H+  +  O2     (1) 
2Co2+/+Pc     2Co3+/2+Pc  +  2e-      (2) 
H2O2       2H
+  +  O2  +  2e
-
                         overall reaction     (3) 
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CoPc is initially in the Co
2+ 
oxidation state (Co
2+
Pc
2-
), it is subsequently electrochemically 
oxidized to Co
3+ 
or reduced to Co
+
 [277]. The structure of CoPc is shown in Figure 3-23. 
 
Figure 3-23: Chemical structure of CoPc. 
 
The principle of operation of the proposed biosensor is illustrated in Figure 3-24. The enzymatic 
generation of H2O2 is achieved by PA-CoA reacting with O2 to produce hexadecanoyl-CoA and 
H2O2 (which is the oxidized by Co
2+ 
to produce Co
3+
).  
 
Figure 3-24: Schematic showing the principle of NEFA biosensor for H2O2 detection using CoPc SPE. 
 
Similar data was obtained for OA-CoA using CoPc SPE in Figure 3-25, with its corresponding 
calibration graph in Figure 3-26. A bar chart highlighting the chronoamperometric currents at 
500 s from both the acylated NEFAs is shown in Figure 3-27. PA-CoA produced more H2O2 
compared to OA-CoA, this maybe due to it being a saturated NEFA. In solution fatty acyl-CoA 
forms micelles, with the critical micelle concentration differing with the chain length, making it 
difficult for the determination of the kinetic parameters of these CoA esters [162]. 
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Figure 3-25: CA at 500 mV of various OA-CoA concentrations on CoPc SPE in 0.1 M phosphate buffer pH 7.4 with 
ACOD in solution. 
 
Figure 3-26: Calibration graph at 500 s. 
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Figure 3-27: Bar chart comparing the current produced from the two different acylated NEFAs on CoPc SPE. CA at 500 
mV, current taken at 500 s. 
 
3.3.3.1 Activity of cobalt phthalocyanine  lost over time 
The activity of CoPc electrode was tested by multiple scans in 0.00 mM PA-CoA (as having no 
H2O2) and in 0.50 mM PA-CoA (in presence of H2O2 produced from the enzymatic reaction with 
ACOD). 75 CV scans were done in each solution at 50 mV s
-1
 scan rate. As the number of scans 
increased the activity of the CoPc SPE decreased, this is has been a feature of the 
metallophthalocyanine catalysts during cycling or long-term measurements attributed to the loss 
of adsorbed transition metal from the surface of the macrocycle [285, 286]. Figure 3-28 shows 
all the scans for 0.00 mM and 0.50 mM PA-CoA, the arrow points to the general pattern over 
consecutive scans. Work done by Van Veen and Colijn showed that oxidation of the macrocycle 
(Fe and Co) by O2 or H2O2 caused the loss of activity [287]. Many catalysts are degraded by 
H2O2, therefore successful potential scans are not fully reproducible, resulting in large number of 
studies with fresh electrode surfaces [288]. Whether or not all these fresh surfaces are identical, 
can complicate the study. So when using CoPc SPE, ideally a fresh electrode would be the best 
practice for each concentration of PA-CoA/H2O2. 
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Figure 3-28: CV of 75 scans of 0.00 mM (black) and 0.50 mM (blue) PA-CoA with ACOD in solution, at scan rate of 50 
mV s-1 using a CoPc SPE. 
 
Parallel to Figure 3-14 and Table 3-1 are Figure 3-29 and Table 3-2 but using CoPc as the SPE. 
At 100 mV s
-1
 the CV shows that increasing to upper potential increases the amount of current 
produced. However Table 3-2 shows that only up to 1.0 V is this pattern observable over the 
whole range investigated on a different electrode. Having more scans loses the activity of the 
CoPc electrode, hence the drop in current at higher potentials. This could be due to desorption of 
CoPc from the electrode, macrocycle becoming destroyed in the presence of oxygen or 
demetallation of the phthalocyanine [285]. 
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Figure 3-29: CV of 0.50 mM PA-CoA with ACOD in solution, at scan rate of 100 mV s-1 using a CoPc SPE with increasing 
upper limit potential varying from 0.6 V to 1.6 V. 
Table 3-2: The current obtained for each scan rate for each upper potential for 0.50 mM PA-CoA. All data is background 
subtracted. Data given in 6 significant figures. 
Upper potential 
(V) 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 5 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 50 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 100 
mV s
-1
 
Current 
produced (A) 
for 0.50 mM 
PA-CoA at a 
scan rate at 500 
mV s
-1
 
0.6 2.95990 9.97620 15.2497 39.9872 
0.8 6.92630 25.2899 34.0027 64.5289 
1.0 20.5990 33.9960 41.9320 67.5050 
1.2 11.4750 96.0700 40.0090 45.5930 
1.4 -56.6710 76.1110 42.1150 -54.9320 
1.6 -55.8470 -63.7810 -32.9590 -98.2600 
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3.3.4 Screen printed electrode comparison 
A comparison table of the 3 substrates (H2O2, PA-CoA and OA-CoA) and 3 electrodes is shown 
in Table 3-3. From the 3 electrodes investigated for electrochemical NEFA detection in solution, 
CoPc showed the highest sensitivity by far, for H2O2 production from NEFA. This is because 
CoPc SPE was the only catalyst modified electrode, thus reducing the excessive voltage required 
to drive the oxidation of H2O2. 
The current produced by H2O2 solution oxidation was always slightly lower, than that from H2O2 
produced from PA-CoA/OA-CoA. However data from H2O2 solution oxidation was more linear 
(higher R
2
 value). H2O2 readily decomposes, this could be the reason why its detection was 
lower from solution, as once the stock solution (10 mM) was made up, there was a bit of a wait 
to have all the concentration chronoamperometrically detected, compared to when PA-CoA/OA-
CoA reacts with O2 and it is detected without delay each time. All three electrodes had a linear 
detection range of 0.00 mM to 3.00 mM of PA-CoA/OA-CoA, covering well above the 
physiological range in human plasma. 
Table 3-3: Comparison of 3 different electrodes for CA at 500 mV at 500 s, current for 0.75 mM PA-CoA/OA-CoA/H2O2. 
 C-SPE CoPc SPE SWCNT SPE 
Detection Current 
(A) 
Sensitivity 
(A/mM) 
R
2
 
Current 
(A) 
Sensitivity 
(A/mM) 
R
2
 
Current 
(A) 
Sensitivity 
(A/mM) 
R
2
 
PA-CoA 0.4011 0.6326 0.9926 0.9477 1.1664 0.9972 0.5651 0.7358 0.9960 
OA-CoA 0.3155 0.6519 0.9799 0.6929 1.1326 0.9944 0.8125 1.0725 0.9961 
H2O2 0.3127 0.5644 0.9943 0.7272 1.0539 0.9993 0.7275 1.2643 0.9963 
 
C-SPE had the most consistent current produced for the 3 substrates at 0.75 mM, with a 
difference of only a minor 0.0884 A. Whereas the SWCNT SPE had the largest difference 
between the substrates of 0.5285 A. The variability between the amount of H2O2 detected by 
the different electrodes renders the C-SPE as the most reproducible and consistent electrode, it 
has no additional bonds on the surface (is a plain carbon electrode) and would be suitable for 
further optimization for NEFA detection. 
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3.3.5 Interferences 
In literature, several molecules were found to cause interference with NEFA level determination 
(with standards and in blood), namely:  phospholipids, bilirubin, albumin, haemoglobin, lecithin, 
lactic acid, acetic acid, ascorbic acid, -hydroxybutyric acids, triglycerides, glutathione, cysteine 
and unreacted Coenzyme A [118, 121, 125, 127, 129-132]. The reason for the interference is 
mainly dependant on the method that is used to detect the NEFA. Details of this are given in 
Table 3-4 below. 
Table 3-4: Suggested reasons why each interference may cause incorrect NEFA readings. 
Interference Method of NEFA detection 
Result on 
reading 
Suggested reason for 
interfering 
References 
Acetic acid Paper chromatography - 
Traces from 
chromatographic solvent 
[130] 
Albumin 
Optical enzymatic assay Negative Inhibits enzyme activity [132] 
Paper chromatography Positive Bound fatty acids [130] 
Colorimetric enzymatic assay Negative Bound fatty acids [289] 
Ascorbic 
acid 
Optical enzymatic assay Negative 
Competition with POD for 
H2O2 
[132] 
Optical enzymatic assay Positive - [121] 
Colorimetric enzymatic assay Negative - [289] 
Bilirubin 
Optical enzymatic assay Positive - [132] 
Colorimetric copper-soap 
method 
Positive Extracted as copper complex [129] 
Colorimetric enzymatic assay Negative - [289] 
Coenzyme A 
Colorimetric enzymatic assay Negative 
Unreacted Coenzyme A 
inhibits subsequent reaction 
[120] 
Optical enzymatic assay Negative [132] 
Colorimetric enzymatic assay Negative [289] 
Haemoglobin Optical enzymatic assay Positive - [132] 
Heparin 
Automated enzymatic 
determination by centrifugal 
analysis 
Positive 
Heparinized plasma falsely 
elevate by 10 % 
[290] 
Lecithin 
Paper chromatography Positive 
Molar extinction produced is 
similar to that of NEFA 
[123, 130] 
Radiochemical assay Positive - [127] 
Phospholipid 
Colorimetric copper-soap 
method 
Positive 
Extracted as copper 
complex, tend to hydrolyse 
[118, 129] 
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Electrochemically many compounds (e.g. acetaminophen, uric acid and ascorbic acid) can be 
oxidised at such high positively applied potentials (500 mV) and would cause interference with 
the H2O2 detection in real blood samples [291]. Adsorption of the listed compounds (or their 
derivatives) is undesirable on the analytical response, particularly on diffusion-controlled mass 
transport. Moreover, adsorption of interferences and/or their derivatives that are non-
electroactive may deactivate the surface of the electrode [276]. Tests were done with selected 
compounds: albumin, urea, uric acid, ascorbic acid, glucose, acetaminophen and aspirin. Some 
general information on each of these is given in Table 3-5. 
Acetaminophen (Paracetamol) was investigated as it is the most common pain killer in the world, 
naturally this would be present in the blood of people who take acetaminophen and then use the 
sensor [292]. The patients with T2D are also in danger of having high cholesterol and inevitably 
leading onto blood pressure problems, so aspirin was investigated, as it is commonly prescribed 
to patients with high blood pressure. Aspirin can also improve insulin sensitivity and lipid 
metabolism [293]. 
The concentrations selected for this study in Table 3-5 are typical ranges, in actual fact patients 
could have elevated concentrations of some of these interferences depending on their medical 
condition, e.g. concentration of urea increases in patients with kidney problems. The ‘chosen 
concentrations’ for urea, uric acid and aspirin were towards the higher end of the range of 
concentration found in blood. This was done to take the concentration fluctuation in different 
patients blood into consideration. The concentration of glucose was 10 mM, which was above 
the normal range. This was chosen to represent a patient with uncontrolled T2D, who would 
have a high glucose concentration. 
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Table 3-5: General information on the chosen interferences. 
Interference Chemical structure 
Concentration in blood  
(mM) 
Chosen 
concentration 
(mM) 
References 
Urea 
(NH2)2CO  
1 - 19 or 2.64-2.71 
3.00 [294, 295] 
Uric acid 
C5H4N4O3 
 
4 – 8.5 8.00 [294, 295] 
Ascorbic acid 
C6H8O6 
 
0.04 – 0.116 or 0.087 – 
0.755 
0.50 [294, 295] 
Glucose 
C6H12O6 
 
4– 8 
Up to 30 
10.0 [296] 
Acetaminophen 
C8H9NO2 
 
0.066 – 0.132 0.12 [297] 
Aspirin 
C9H8O4 
 
0.1 – 0.3 or 1.08 – 2.17 3.00 [295, 298] 
Albumin - 52 – 65% of total protein 0.60 [295] 
 
Using chronoamperometry with C-SPE at 500 mV, the current at 500 s was compared with that 
of 0.20 mM PA-CoA and with that of 0.20 mM PA-CoA spiked with each interferant 
individually (each concentration used was the ‘chosen concentration’ in Table 3-5). The result is 
shown in Figure 3-30, along with a zoomed in version of lower current range. 
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 Figure 3-30: CA at 500 mV for 0.20 mM PA-CoA with ACOD, spiked with various interferences on C-SPE, in 0.1 M 
phosphate buffer pH 7.4. The concentration of each interference is that listed in Table 3-5. 
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Table 3-6 shows the percent interference worked out for each compound studied. This was 
calculated by the current produced with the spiked sample during CA at 500 s, divided by the 
current produced from 0.20 mM PA-CoA at 500 s, times 100 (to get a percentage interference). 
Before this could be done, various concentrations of each interference only were tested on the C-
SPE. This data is shown in the appendix (in Figure 7-2 to Figure 7-5) and the data is summarised 
in Table 3-6. The detection range given here is based on the linear detection of that interference 
on a C-SPE. The sensitivity is the sensitivity of C-SPE at various concentrations within the 
detection range. 
Table 3-6: Each interference at 500 s CA at 500 mV. 
Compound 
Sensitivity 
(A/mM) 
R
2
 
Detection 
range (mM) 
% interference with 
0.20 mM PA-CoA 
Urea 0.0017 0.9675 0 - 10 4.6 
Uric acid 4.5579 0.9808 1 - 10 15218 
Ascorbic acid 1.3313 0.9777 0.1 - 1 218 
Glucose 0.0026 0.7265 0 - 30 38.3 
Acetaminophen 2.6588 0.9980 0 - 0.18 78.5 
Aspirin 0.0043 0.9836 0 - 3 80 
Albumin 0.0205 0.9968 0.2 – 0.6 -75 
 
The increase in the percentage detection of 0.20 mM PA-CoA was caused by either the 
interference interacting with the enzymatic reaction or by the interference altering the surface of 
the electrode, leading to an increased current reading of H2O2 oxidation. 
Most interference with NEFA detection was caused by uric acid and ascorbic acid due to the 
high overpotential required for the oxidation of H2O2 being similar to that of the oxidation of 
these compounds. The impact of uric acid and ascorbic acid will be discussed in more detail 
later.  
All interferences studied caused an increase in the current except albumin. Bovine serum 
albumin (BSA) is a single polypeptide chain consisting of about 583 amino acid residues and no 
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carbohydrates. At pH 5-7 it contains 17 intrachain disulfide bridges and 1 sulfhydryl group [299, 
300]. Each serum albumin protein molecule can carry seven fatty acid molecules [301]. Serum 
albumin interacts strongly with fatty acid anions [302]. The cationic sites on the albumin 
molecule is probably where the fatty acid anions bind to. The availability of such cationic sites 
will depend on their equilibrium with hydrogen ions. Albumin is the major vehicle for NEFA 
transport through the plasma [303]. Albumin hindered the activation of acylated NEFA by 
ACOD by forming a complex with the fatty acid, hence lower amount of H2O2 produced [155].  
On a bare electrode the oxidations of ascorbic acid and uric acid occur at close potentials and the 
bare electrode very often suffers from fouling effects [304]. To reduce the potential interference 
and fouling effects of these compounds, the immobilization of the enzymes ACS and ACOD on 
the working electrode may be a step forward in the development of the NEFA electrochemical 
biosensor. Then oleic acid/palmitic acid can be used (step 1 from scheme 1) instead of OA-
CoA/PA-CoA (step 2 from scheme 1), as they are the most abundant NEFAs present in the 
patient’s blood.  
Immobilization of enzymes on the WE would reduce the amount of enzyme used and increase 
the repeatability of using one electrode for multiple concentrations. This would bring the cost 
down in sensor development and in this research. Once the enzyme is bound to the surface of the 
SPE’s WE, it is more likely to react with the substrate and cause H2O2 production and 
subsequent oxidation. 
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3.4 Conclusions 
 
In this chapter H2O2 oxidation and H2O2 oxidation from the NEFA enzymatic reaction was tested 
on 3 SPE’s (C-SPE, CoPc and SWCNT SPE) and compared. All electrodes had a good response 
to the various concentrations investigated (up to 3.00 mM PA-CoA/OA-CoA). Linear calibration 
graphs of LSV at 500 mV and CA at 500 s at 500 mV potential were obtained. In all 3 SPE’s the 
limit of detection was 0.00 mM to 3.00 mM PA-CoA/OA-CoA. This covers the range of NEFA 
concentrations in human blood, for sensor development. 
LSV’s were used to determine the order of reaction by plotting log j vs. log PA-CoA/OA-CoA 
concentration range for each electrode investigated. The potentials investigated (400 mV plus) 
proved to be first order, with correlation coefficient (R
2
) around 0.99. 
The current produced for H2O2 oxidation was evident at 300 mV plus. Which is why the set 
potential of 500 mV was chosen for all CA work. 
Activity of CoPc electrode was lost over time, meaning that the SPE could only be used once to 
provide a reliable current. 
Upper potential range was investigated for C-SPE and CoPc SPE. The higher the potential the 
more the current was produced using CV at 100 mV s
-1
 scan rate. But having a very high upper 
potential would have many side reactions too, so all LSV experiments were to be done up to 600 
mV for future work. 
The C-SPE electrode was taken forward and tested with common interferences that would be 
present in blood (urea, uric acid, ascorbic acid, glucose, acetaminophen, aspirin and albumin). 
From which urea had the least interference and uric acid had the most, as predicted from its 
highly oxidizable nature. 
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4 Enzyme electrode for NEFA detection 
4.1 Introduction 
The working electrode (WE) of screen printed electrodes (SPE’s) can be readily modified to 
enhance selectivity and/or sensitivity by surface deposition of various substances, such as 
polymers and enzymes [305]. Carbon screen printed electrodes (C-SPE’s) are suitable for a 
variety of applications, they are substrates for biosensors due to the large potential window of 
carbon, the low background current, chemical inertness and ease of derivitization and 
modification. The immobilization method may affect the sensitivity, response time, stability and 
reproducibility of biosensors [306]. The method needs to ensure the enzyme is retained on the 
support, with the active site maintaining its functionality and accessibility. 
Carbon nanotubes (CNT) may be used to help achieve this, but they first need to be properly 
functionalized and immobilized [268]. Untreated CNT have high hydrophobicity and tend to 
assemble into bundles, limiting their usage and process ability [307]. Multiwall carbon nanotubes 
(MWCNT’s) are coaxial assemblies of graphene cylinders with dimensions ranging from 2 to 30 
nm and length of several microns [308]. CNT have poor solubility in usual solvents, so having 
polymer wrapped CNT improves solubility, is non-destructive and the electrocatalytic properties 
are retained [309]. Polymer/CNT composites prepared non-covalently retain their unique 
properties and can develop new materials [310]. Poly(dimethyldiallylammonium chloride) 
(PDA) is a water-soluble, quarternary ammonium, cationic polyelectrolyte (structure shown in 
Figure 5-2 later). This polymer when dissolved in aqueous solutions acts as a positively charged 
colloid [208]. It is a dispersant of MWCNT’s and is readily coated on negatively charged surface 
of MWCNT’s. The CNT have multiple roles [311]:  
 they are a substrate to immobilize the enzyme 
 electrocatalytic oxidation/reduction of H2O2 at the CNT surface, reduced over voltage 
and avoids interference from other co-existing interactive species 
 enhance signal due to fast electron transfer and large working surface area. 
The immobilization of biomolecules on electrodes is a big factor in the progress of 
electrochemical biosensors [312]. The functionality of the biomolecule must stay intact along 
with the ease of access to its active site. There are several immobilisation methods for biological 
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molecules, and no single method is right for all the different molecules or purposes [204]. Figure 
4-1 schematically shows the various immobilization techniques. 
 
Figure 4-1: Schematic representation of various immobilization techniques: (A) covalent binding, (B) adsorption, (C) gel 
entrapment, (D) cross-linking, (E) microencapsulation and (F) adsorption-cross-linking [204]. 
The immobilization technique is responsible for the sensitivity, response time, long-term stability 
and reproducibility of the biosensor. Immobilization methods, for example physical adsorption, 
covalent binding, carrier binding, entrapment within a polymeric matrix, encapsulation and 
cross-linking, could engage in numerous point attachments, failure of biomolecule activity, 
biomolecule leaking, random biomolecule dis-configuration and great diffusion barriers [313]. 
These can consequently cause the biosensor to be poorly sensitive, unstable and have long 
response times. Which is not ideal for NEFA biosensor development. 
4.1.1 Layer-by-layer immobilization 
The layer-by-layer (LbL) assembly technique for multicomposite films was first produced by 
Decher and group in 1991 [314]. LbL self-assembly technique is a simple procedure, with a wide 
choice of methods along with film composition, number of layers and thickness control. It takes 
advantage of the charge-charge interaction between the substrate and monolayers, creating 
multiple layers held together by strong electrostatic forces/interactions. LbL films provide 
favourable nanoenvironments for the enzymes/proteins and boost the direct exchange between 
the proteins and electrode [315]. In this work the multilayer assemblies consisted of alternating 
adsorption of anionic (the enzymes ACS and ACOD) and cationic (PDA-MWCNT) 
polyelectrolytes (electrostatic attraction of oppositely charged species) [316]. LbL method allows 
fine thickness control of enzymatic layers (at molecular or nanometer level), avoiding mass 
77 
 
transport problems between the analyte and electrode surface (this also affects the response time 
of biosensors) [216, 317, 318]. The adsorption of molecules having more than 1 equal charge 
allows charge reversal on the surface [314]. This gives: 
 Repulsion of molecules that carry the same charge, the adsorption is therefore self-
regulated and confined to a single layer 
 On top of this layer, molecules with the opposite charge can be adsorbed. Building 
multiple films. 
Salt (NaCl) is used in the solution in which polyelectrolyte multilayers are formed, known to 
participate in the formation and function of the layers [319]. The concentration of NaCl controls 
the thickness increment per deposition cycle, permeability and stability. NaCl counterions 
participate in charge neutralization leading to more equilibrated conformation of polymer chains 
[314]. The mobility of charge-paired polyelectrolyte chains are improved with higher NaCl 
concentrations. There is an equilibrium set-up between the “intrinsically” charge compensated 
polyelectrolyte complex, Pol
-
Pol
+
, where the polymer segments balance the internal charge, and 
an “extrinsically” compensated form, Pol+Cl-/Pol-Na+. 
Pol
+
Pol
-
m + Na
+
aq + Cl
-
aq  Pol
+
Cl
-
m + Pol
-
Na
+
m 
m = multilayer phase 
Addition of NaCl dramatically increases the amount of polyelectrolyte deposited [320]. 
There are four effects on the kinetic behaviour of an immobilized enzyme [321]: 
1. Conformation and steric modification 
2. Partitioning of reactant 
3. Microenvironmental effects on intrinsic catalytic properties 
4. Effects of diffusion or mass transfer 
To understand characteristics of the immobilized enzymes, understanding the amount adsorbed, 
the kinetic behaviour of the enzyme regarding the support, the procedure used to immobilize the 
enzymes and the rate of substrate mass transport needs to be investigated [322]. 
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4.1.2 H2O2 detection via layer-by-layer 
A review paper was published by Zhao et al. highlighting the progress made on the 
electrochemical biosensors based on this LbL technique [216]. A few have been made to detect 
H2O2 oxidation/reduction from the enzymes that have been immobilized on the electrodes. Table 
4-1 shows these selected sensors for H2O2 detection. There are multiple LbL assembly methods, 
the immobilization could be based on one of the following: electrostatic force, biological 
interaction (e.g. avidin-biotin, lectin-sugar, antibody-antigen), cross-linking, covalent binding 
and electrodeposition. 
Table 4-1: Electrochemical biosensors based on LbL assembly methods for H2O2 detection. 
Sensor for 
Electrode 
fabrication 
Electrode 
Amperometric 
potential at H2O2 
oxidation/reduction 
Abbreviations Reference 
Cholesterol 
(PAH-MWCNT-
GNPs/HRP)/(PAH-
MWCNT-
GNPs/ChOx) 
gold 
-0.15 V vs. calomel 
electrode 
- H2O2 Reduction 
PAH = poly(allylamine 
hydrochloride) 
GNPs = gold nanoparticles 
ChOx = cholesterol oxidase 
[323] 
Cholesterol (PDA/ChOx) gold 
+ 0.70 V 
- H2O2 Oxidation 
PDA = poly 
(diallyldimethylammonium 
chloride) 
[324] 
Glucose 
(PAH-
MWCNT/HRP/ 
ConA/GOx) 
gold 
-0.15 V vs. saturated 
calomel electrode 
- H2O2 Reduction 
HRP = horse radish peroxidase 
ConA = concanavalin A 
GOx = glucose oxidase 
[325] 
Glucose 
(CNT/PDA/GOx 
/PDA) 
glassy 
carbon 
-0.10 V vs. Ag/AgCl 
- H2O2 Reduction 
 [311] 
Glucose 
(MPS-PDA/PSS/ 
PDA-MWCNT/ 
GOx) 
gold 
-0.20 V 
- H2O2 Reduction 
MPS = 3-mercapto-1-
propanesulfonic acid, sodium 
salt 
PSS = poly(sodium 4-
styrenesulfonate) 
[326] 
Glucose (HRP/GOx) 
glassy 
carbon 
-0.20 V vs. Ag/AgCl 
- H2O2 Reduction 
 [327] 
Acetylcholine 
(PDA-AChE/ 
GNPs/MWCNT) 
platinum 
+ 0.60 V vs. 
Ag/AgCl 
- H2O2 Oxidation 
AChE = acetylcholinesterase [328] 
Acetylcholine (AChE/ChOx) platinum 
+ 0.60 V vs. 
Ag/AgCl 
- H2O2 Oxidation 
ChOx = choline oxidase [329] 
H2O2 PVP–Os/HRP gold 
+ 0.35 V vs. 
saturated calomel 
electrode 
- H2O2 Oxidation 
PVP–Os = quaternized poly(4-
vinylpyridine) 
[330] 
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4.1.3 Experimental 
Materials 
Acyl-Coenzyme A synthetase (ACS) 4 U/mL of enzyme was purchased from Wako HR-series 
NEFA-HR(2) enzymatic NEFA assay kit (Neuss, Germany). In 30 L of solution, 0.12 U ACS 
was present. Oleic acid (OA) was the Wako NEFA standard solution (cat # 276-76491) also 
purchased from Wako HR-series NEFA-HR(2) enzymatic NEFA assay kit (Neuss, Germany). 
This comes as a 1 mM stock solution. 
ACOD was purchased from Wako Japan at 100 Units, CAS # 61116-22-1 (Neuss, Germany). 
Stock solution of 4 U/mL with 0.20 M NaCl was prepared with phosphate buffer as the diluent. 
PA-CoA, OA-CoA, ATP and Coenzyme A (CoA) were purchased from Sigma Aldrich (Dorset, 
UK). Stock solutions of the solutions PA-CoA (10 mM), OA-CoA (10 mM), ATP (20 mM) and 
CoA (20 mM) were made by diluting in 0.1 M phosphate buffer solution (PBS), pH 7.4 and 
stored at -20 
o
C until use. 
Potassium ferricyanide (III) and potassium ferrocyanide was also purchased from Sigma Aldrich 
(Dorset, UK). 10 mM stock solution was prepared, for electrochemical impedence spectroscopy 
(EIS) measurements 5 mM 1:1 mixture of K3Fe(CN)6 : K4[Fe(CN)6] was used. 
PDA solution consisted of 1 % PDA solution, with 0.20 M NaCl in 5 mL distilled water. PDA 
was purchased from Sigma-Aldrich (Germany). 
A poly(dimethyldiallylammonium chloride)-MWCNT (PDA-MWCNT) solution was prepared 
by taking 3 mg of MWCNT’s and placing in 5 mL of 1 % PDA solution, with 0.20 M NaCl and 
sonicating for 3 hours [309, 331]. The suspension was left overnight and the upper layer was 
used as the PDA-MWCNT solution. The bottom layer was discarded as it contained unbound 
MWCNT’s. The dispersion of MWCNT in positively charged (polycation) PDA is possibly due 
to weak supramolecular interactions between them, which bind electrostatically to the negatively 
charged (polyanion) ACOD or ACS at pH 7.4, as the isoelectric point of ACOD is 5.5 and ACS 
is 6.27 [270, 307, 332]. 
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The C-SPE (model DRP-C110), CoPc SPE (model DRP-410) and SWCNT SPE (model DRP-
110SWCNT) were purchased from DropSens (Oviedo, Spain). 
The electrodes have a WE diameter of 0.40 cm and an area of 0.13 cm
2
. The reference electrode 
is silver/silver ion (Ag) and the counter electrode is carbon. The dimensions of the electrodes are 
3.40 x 1.00 x 0.05 cm (Length x Width x Height) respectively. These disposable electrodes were 
used as purchased with no pre-treatment required. 
Electrochemical measurements 
Electrochemical measurements were run on the Autolabs (PGSTAT101 and PGSTAT302) with 
NOVA 1.8 as the software package installed. Cyclic Voltammetry (CV) was done using a scan 
rate of either 5 mV s
-1
 or 50 mV s
-1
. The potential range investigated was from -800 mV to 500 
mV or to 600 mV. Linear Sweep Voltammetry (LSV) was done using a scan rate of 1 mV s
-1
. 
The potential range investigated was from 0 mV to 600 mV. As stated in the previous section all 
calibration graphs will be at 500 mV. Chronoamperometry (CA) was done at a set potential of 
500 mV with a step potential of 0.25 seconds (s) and duration of 1500 s. All CA calibration 
graphs will be at 500 s. 
For EIS measurements a 5 mM 1:1 mixture of K3[Fe(CN)6] : K4[Fe(CN)6] was used as the redox 
probe, with the frequency range set between 0.1 – 100 000 Hz, along with 10 mV as the 
amplitude of alternating voltage. The fixed potential was 0.17 V. 
The electrolyte used was 0.1 M phosphate buffer (pH 7.4). 
All electrochemical experiments were done at room temperature, in at least duplicates wherever 
there are error bars. Error bars were worked out based on the average, the positive error was the 
most positive result minus the average, the negative error was the average minus the most 
negative result. 
Fabrication of (PDA-CNT/ACOD)2 and (PDA/ACOD)2 electrodes 
For electrode modification, an O-ring was used to expose just the surface of the WE and hide the 
reference electrode and counter electrode, to ensure immobilization occurred on the WE only. 
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To assemble enzyme electrode (PDA-MWCNT/ACOD)2, 15 L of PDA-MWCNT solution was 
dropped onto the WE, after 30 mins of storage in the fridge, the electrode was washed with 10 
L PBS solution (pH 7.4),  then 30 L of ACOD solution was dropped. The electrode was 
washed with 20 L PBS solution (pH 7.4). The whole process was repeated once more to make 
(PDA-MWCNT/ACOD)2 electrode. Between each addition the electrode was kept in the fridge 
at 4 
o
C for 30 minutes. Enzyme loading can be estimated to increase when there are more layers, 
but the exact amount cannot be worked out, as the electrode was washed with PBS before the 
next layer. 
To assemble enzyme electrode (PDA/ACOD)2, the same procedure as the (PDA-
MWCNT/ACOD)2 electrode was used, just the PDA-MWCNT solution was replaced with PDA 
solution. A schematic of this is shown in Figure 4-2 below. 
 
Figure 4-2: Schematic display of the LbL fabrication of (PDA/ACOD)2 on C-SPE WE. 
 
Fabrication of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 electrodes 
Again for electrode modification, an O-ring was used to expose just the surface of the WE. To 
assemble enzyme bilayers (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 on the electrodes, 15 
L of PDA-MWCNT solution was dropped onto the WE, then 30 L of ACOD solution was 
dropped, then 15 L of PDA-MWCNT solution and then lastly 30 L of ACS. A schematic of 
this fabrication is shown in Figure 4-3. The electrode was washed with PBS solution (pH 7.4) 
between each dropping and the excess solution was removed as it was not properly bound to the 
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surface of the electrode. Between each addition the electrode was kept in the fridge at 4 
o
C for 30 
minutes. The whole process was repeated another 3 times to make (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)4 electrode for the EIS measurements. 
 
Figure 4-3: Schematic display of the LbL fabrication of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 on C-SPE WE. 
To assemble enzyme bilayers on the electrodes (PDA-MWCNT/ACS/PDA-MWCNT/ACOD)1, 
the same procedure as above was repeated but with the enzyme order switched. This was done to 
optimise the enzyme electrode and to work out which configuration would give the best result in 
terms of sensitivity and current. 
To assemble 1 single enzyme layer on the electrodes (PDA-MWCNT/ACOD+ACS)1, 15 L of 
PDA-MWCNT solution was dropped onto the WE, then 30 L of ACS solution and 30 L of 
ACOD solution was dropped together. Again the electrode was washed with PBS solution (pH 
7.4) between each dropping. Between the two additions the electrode was kept in the fridge at 4 
o
C for 30 minutes immersing time. This electrode was tested for the same reasons as the (PDA-
MWCNT/ACS/PDA-MWCNT/ACOD)1 electrode and had an additional advantage of taking 1 
hour less to fabricate. 
For the (PDA/ACOD/PDA/ACS)1 electrode, the same procedure as (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 was used but the PDA-MWCNT solution was replaced 
with PDA solution. This electrode was fabricated to test whether there are any additional benefits 
of incorporating MWCNT in this work and if not this would save money in the cost of 
fabrication. 
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4.2 Enzyme fabricated electrodes for PA-CoA/OA-CoA detection 
Figure 4-4 shows the LSV at the C-SPE electrode modified with (PDA-MWCNT/ACOD)2 film 
with different concentrations of OA-CoA (up to 1.50 mM). The current increased with increasing 
concentrations of OA-CoA. A calibration graph obtained at 500 mV exhibited a linear 
correlation (R
2 
= 0.98) between the OA-CoA concentration (up to 0.75 mM) and the oxidation 
current, which is from the H2O2 produced by OA-CoA oxidation by ACOD and oxygen. This is 
in agreement with the solution study in section 3.3. It indicates that the activity of ACOD was 
retained within the PDA-MWCNT multilayer, and the enzyme electrode can be used to 
determine OA-CoA concentrations.  
However the concentration range and the sensitivity here are much lower when compared to that 
of the work in solution. This could be due to the reduced volume/concentration of ACOD 
immobilised on the surface of the electrode compared to that which was present in solution. The 
same fabricated electrode was used for all the 8 concentrations investigated, over time ACOD 
was being used and could be lost to the solution and not be bound on the surface of the electrode. 
Figure 4-4: LSV for various concentrations of OA-CoA measured at a C-SPE modified with (PDA-MWCNT/ACOD)2 in 
0.1 M phosphate buffer pH 7.4, scan rate 1 mV s-1. Inset:  calibration graph at E = 500 mV. 
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A slope of 0.42 was obtained at a potential of 500 mV from the plot of log j against log [OA-
CoA] in Figure 4-5. Indicating that it’s a second order rate of reaction. The R2 was between 
~0.88 and 0.99 for all the potentials in the graph. 
 
Figure 4-5: The relationship between log j and log OA-CoA concentration on the (PDA-MWCNT/ACOD)2 electrode  at 
various electrode potentials in 0.1 M phosphate buffer pH 7.4. 
 
Parallel to Figure 4-4, linear sweep voltammetry were carried out in 0.1 M PBS with various PA-
CoA concentrations, shown in Figure 4-6. The oxidation currents for potentials above 400 mV 
exhibited a linear increase as the PA-CoA concentration increased. A calibration curve obtained 
at 500 mV exhibited a linear range (R
2 
= 0.99) in the same concentration range of PA-CoA (inset 
Figure 4-6).  
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Figure 4-6: LSV for various concentrations of PA-CoA measured at a C-SPE modified with (PDA-MWCNT/ACOD)2 in 
0.1 M phosphate buffer pH 7.4, scan rate 1 mV s-1. Inset: calibration graph at E =  500 mV. 
 
Slopes of ~ 0.5 were obtained at all the potentials investigated from the plot of log j against log 
[PA-CoA] in Figure 4-7. Indicating a reaction order of 0.5 with respect to PA-CoA. Same as that 
with OA-CoA. The R
2 
value was between ~0.98 and 0.99 for all the potentials in the graph. 
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Figure 4-7: The relationship between log j and log PA-CoA concentration on the (PDA-MWCNT/ACOD)2 electrode  at 
various electrode potentials in 0.1 M phosphate buffer pH 7.4. 
 
The enzyme electrode (PDA-MWCNT/ACOD)2 is selective for OA-CoA and PA-CoA detection 
individually. Figure 4-8 shows the current difference between the two different acylated NEFAs. 
The current obtained from PA-CoA was predominantly higher than that from OA-CoA, PA-CoA 
is from a saturated NEFA, this may have a better interaction with the enzyme electrode 
compared to the unsaturated OA-CoA. This difference in current production is higher than the 
current difference which was produced from the two acylated NEFAs in the solution work, 
indicating that immobilisation of ACOD results in even more selectivity. Another reason for this 
difference is, as more concentrations were run using the same immobilised electrode, more 
ACOD was being used and lost into solution rather than being retained on the surface of the WE, 
resulting in having less ACOD then there was to begin with in the subsequent concentrations. A 
better comparison would be to run each concentration on a freshly fabricated electrode, but this 
would use up resources. 
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Figure 4-8: Bar chart comparing the current produced from the two different acylated NEFAs on (PDA-
MWCNT/ACOD)2 electrode. LSV at 1 mV s-1, current taken at 500 mV. 
The enzyme electrode (PDA-MWCNT/ACOD)2 was fabricated to test whether the feasibility of 
immobilizing ACOD onto the WE of the C-SPE was possible. The next thing to consider would 
be to test whether having both ACOD and ACS immobilised on a C-SPE is possible. Then 
NEFA could be tested in one step, rather than relying on individual steps/reactions. A sensor is 
needed for the detection of NEFA and not for the detection of acylated NEFA, which is what the 
current (PDA-MWCNT/ACOD)2 electrode does. 
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4.3 Enzyme fabricated electrodes for OA detection 
4.3.1 Determination of OA using (PDA-MWCNT/ACOD/PDA-MWCNT/ACS) fabricated 
electrode 
Both the enzymes ACOD and ACS were immobilized with PDA-MWCNT using the method 
described in Figure 4-3. The LSVs from various OA concentrations on C-SPE fabricated with 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 are shown in Figure 4-9. The calibration graph 
of this electrode (Figure 4-10) at 500 mV showed a good linear correlation between the different 
OA concentrations and the subsequent oxidation currents obtained, indicating a promising 
method for determining NEFA with one operating step. The average sensitivity of the data from 
Figure 4-9 was 1.7222 A/mM and the linear detection range was 0.10 – 0.90 mM OA. 
The peak around 350 mV is due to the ACS enzyme used from the commercial Wako NEFA kit 
as it is not present in blank PBS only when the electrode is not fabricated. Confirmation of this is 
given in Figure 4-12. CV showed that this was not a redox peak. Wako solution A contains: 0.53 
U/mL ACS (Pseudomonas sp.), 0.31 mM Coenzyme A (CoA, Candida), 4.30 mM ATP 
(Bacterium sp.), 1.50 mM 4-aminoantipyrine, 2.60 U/mL ascorbate oxidase (pumpkin), 0.062% 
sodium azide and 50 mM phosphate buffer, pH 7.0 [143]. The nature of the peak maybe due to 
any one of these compounds, as electrochemistry is a very sensitive technique, one of these 
compounds is being oxidised irreversibly at around 350 mV. By a process of elimination, buying 
each listed ingredient of Wako solution A individually and testing it via LSV on a C-SPE would 
help work out which compound this peak was originating from. 
Figure 4-11 shows the plot of log j against log [OA]. Indicating a reaction order of ~0.5 with 
respect to OA. The R
2
 value was ~0.98 for all the potentials in the graph. 
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Figure 4-9: LSV of various concentrations of OA measured at a C-SPE modified with (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4 and 1 mM ATP and CoA, scan rate 1 mV s
-1. 
 
Figure 4-10: Calibration graph at 500 mV. 
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Figure 4-11: The relationship between log j and log OA concentration on the (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)1 electrode  at various electrode potentials in 0.1 M phosphate buffer pH 7.4. 
 
Figure 4-12: LSV at 1 mV s-1 on C-SPE with 100 L PBS only and with 100 L of ACS solution A from Wako kit. 
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Figure 4-9 consisted of around 1:1:1 molar ratio of OA:CoA:ATP, respectively. Although the 
maximum concentration of OA detected was 0.90 mM, so CoA and ATP were still 0.10 mM in 
excess. Validation of this enzyme electrode could be tested by LSV detection of different OA 
concentrations on a newly fabricated enzyme electrode and the current obtained by those 
electrodes plotted on a calibration graph of Figure 4-10. This addition has been shown in Figure 
4-13. Two other OA concentrations (shown in green) were measured on a different electrode and 
plotted on the same graph. The error bars are due to repeats done on other immobilised 
electrodes (each concentration has been tested in twice on different electrodes – in total 4 
electrodes used for this graph – 2 for the measurements in green and 2 for those in black). The 
results shown in green fitted well on the calibration graph, validating the electrode as a means of 
interpreting unknown OA concentrations. 
 
Figure 4-13: Calibration graph obtained by electrochemical measurement of various concentrations of OA at E = 500 mV 
(as shown in Figure 4-9). 0.30 mM and 0.60 mM were measured independently on a different electrode (shown in green).   
 
The CA at 500 mV of this bienzyme fabricated electrode is shown in Figure 4-14, with the 
calibration graph having R
2
 of 0.99 (Figure 4-15). Linear current responses were obtained in both 
the LSV and CA for OA detection parallel to the work in solution. This is the platform for the 
further detection of NEFA on immobilized electrodes. Both these electrochemical detection 
techniques are reproducible, with a R
2
 of ~0.99. 
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Figure 4-14: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1, in 0.1 M phosphate buffer pH 7.4 with 1 mM ATP and CoA. 
 
 
Figure 4-15: Calibration at 500 s. 
 
y = 0.6562x - 0.0135 
R² = 0.9883 
SD = 0.2386 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
i 
/
A
 
OA concentration /mM 
93 
 
To confirm that the enzymatic reaction needs all the substrates to work, several concentrations of 
OA were tested chronoamperometrically at 500 mV without 1 mM ATP and CoA. The barchart 
in Figure 4-16 shows the current comparison at 500 s. This confirms that ATP and CoA are 
needed for the enzymatic reaction to take place and produce H2O2. The slight increase in current 
for 0.50 mM OA maybe due to the slight production of H2O2, as the Wako ACS solution which 
was used to immobilise the electrode contained a small amount of CoA and ATP. However this 
current was not as much as that produced with 1 mM ATP and CoA. 
 
Figure 4-16: Current comparison with and without ATP and CoA on (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 
electrode, CA at 500 mV, current taken at 500 s. 
 
Following from the fabrication of this electrode, other similar bienzyme electrodes were also 
fabricated. The electrode with (PDA-MWCNT/ACS/PDA-MWCNT/ACOD)1 fabrication 
showed linear correlation with H2O2 oxidation too as shown in Figure 4-17. The calibration 
graph is shown in Figure 4-18. However on this electrode the lower limit of detection dropped to 
0.25 mM OA from 0.10 mM OA (0.00 mM and 0.10 mM were coeluted). Figure 4-19 shows the 
CA at 500 mV of (PDA-MWCNT/ACOD+ACS)1 fabricated electrode. This electrode contained 
less PDA-MWCNT yet still maintained good linearity with varying OA concentrations. The 
calibration graph (Figure 4-20) gave a R
2
 value of ~0.98, almost the same as that of Figure 4-18. 
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Figure 4-17: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACS/PDA-MWCNT/ACOD)1 in 0.1 M phosphate buffer pH 7.4 with 1 mM ATP and CoA. 
 
Figure 4-18: Calibration graph at 500 s. 
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Figure 4-19: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD+ACS)1 in 0.1 M phosphate buffer pH 7.4 with 1 mM ATP and CoA. 
 
Figure 4-20: Calibration graph at 500 s. 
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Table 4-2 shows the comparison of the 3 different fabricated electrodes, the current produced 
from 0.90 mM OA is given as an example from each fabricated electrode. The electrode 
consisting of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS) has the highest current produced for 
OA detection. This might be due to the fabrication being in the order of enzymatic reaction (ACS 
for acylation before ACOD for oxidation). This electrode also had the highest sensitivity and R
2
 
value.  
Having both the enzymes mixed together (PDA-MWCNT/ACOD+ACS)1 had the second 
highest current produced. The PDA polymer was able to retain both enzymes on the surface of 
the electrode. For the fabrication of this electrode, both enzymes would be attracted to the 
positively charged polymer and would compete for the same area. Both enzymes have different 
isoelectric points, at pH 7.4, more ACOD would be attached to the polymer than ACS because it 
has a lower isoelectric point. The proportion of ACOD and ACS may not be equal on this 
electrode, which might be why this electrode had lower current and sensitivity when compared to 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS) electrode. 
The (PDA-MWCNT/ACS/PDA-MWCNT/ACOD) electrode had the lowest sensitivity to OA 
detection, lowest current for 0.90 mM OA and the narrowest linear detection range (from 0.25 – 
0.90 mM). Putting all this information together highlights the (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) electrode as the one to take forward for NEFA sensor development. Although 
the layers of immobilized polymer and enzyme are very thin (1-2 nm) on the surface of the 
electrode, this configuration was favoured, this could be due to the thickness of layers and 
orientation of enzyme order favouring the reaction with OA [331]. 
 
Table 4-2: Comparison of CA at 500 mV at 500 s for OA on 3 different fabricated electrodes. 
Electrode fabrication 
Sensitivity 
(A/mM) 
R
2
 value 
Linear detection 
range (mM) 
Current for 0.90 
mM OA (A) 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) 
0.6562 0.9883 0.10 – 0.90 0.5756 
(PDA-MWCNT/ACS/PDA-
MWCNT/ACOD) 
0.2108 0.9851 0.25 – 0.90 0.1723 
(PDA-MWCNT/ACOD+ACS) 0.3616 0.9828 0.10 – 0.90 0.3198 
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4.3.2 Comparison of different SPE’s performance using molar ratios 
As the detection of NEFA is based on an enzymatic reaction the effect of molar ratios were 
investigated. 1:2:2 molar ratio of OA:CoA:ATP was explored for C-SPE, CoPc SPE and 
SWCNT SPE. Both LSV and CA were carried out for this molar ratio. Using LSV the validation 
of 2 different concentrations (0.30 mM and 0.60 mM OA) on a different electrode were also 
independently tested. 
The fully balanced molar reactions are shown below: 
OA + CoA  Oleoyl-CoA + water  
C18H34O2 + C21H36N7O16P3S  C39H68N7O17P3S + H2O 
ATP  AMP + PPi 
C10H16N5O13P3  C10H14N5O7P + P2O7
4-
 
PPi + water  2Pi 
P2O7
4-
 + H2O  2PO4
3-
 
Oleoyl-CoA + oxygen  Enoyl-CoA + hydrogen peroxide  
C39H68N7O17P3S + O2  C39H66N7O17P3S + H2O2 
For the reaction to occur the molar ratio of OA: CoA: ATP should be 1:1:1. Theoretically to have 
a higher chance of reaction the OA: CoA: ATP molar ratio should be 1:2:2 (excess substrates 
increase likelihood of reaction). Table 4-3 and Table 4-4 show the comparison of the current 
produced at the different molar ratios on fabrication of (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)1 bienzyme electrode on the 3 different electrodes investigated, along with each 
electrodes sensitivity and correlation coefficient determination (R
2
). The 0.75 mM OA current 
values in the tables are averaged from two repeats. C-SPE produced the highest current in both 
the molar ratios. This would be the best electrode moving forward with the sensor, followed by 
the SWCNT SPE then the CoPc SPE. The CA showed almost 3 times higher current when 
switching the CoA and ATP to 2 mM for C-SPE. However as the maximum concentration that 
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can be detected when using 2 mM CoA and ATP is 0.75 mM OA, the 1:1:1 molar ratio is 
sufficient for good, reproducible NEFA detection electrochemically. 
The highest sensitivity was given by the C-SPE in both the CA and LSV data, this was followed 
by the SWCNT SPE and then by the CoPc SPE. The highest R
2
 value for the 1:1:1 molar ratio 
was for the C-SPE. The C-SPE showed the best data for the development of the NEFA sensor. 
Table 4-3: Comparison of 3 different electrodes for CA at 500 mV at 500 s, current for 0.75 mM OA. 
 C-SPE CoPc SPE SWCNT SPE 
Molar ratio 1:1:1 1:2:2 1:1:1 1:2:2 1:1:1 1:2:2 
Current 
(A) 
0.4751 1.5514 0.2956 0.6527 0.4035 0.7588 
Sensitivity 
(A/mM) 
0.6562 2.0296 0.3372 0.9653 0.5380 1.0120 
R
2
 0.9883 0.9884 0.8675 0.9194 0.9869 0.9934 
SD 0.2386 0.6095 0.1309 0.2965 0.3122 0.2987 
Detection 
range (mM) 
0.10 – 0.90 0.05 – 0.75 0.25 – 0.75 0.25 – 0.75 0.10 – 0.75 0.00 – 0.75 
 
Table 4-4: Comparison of 3 different electrodes for LSV at 1 mV s-1 at 500 mV, current for 0.75 mM OA. 
 C-SPE CoPc SPE SWCNT SPE 
Molar ratio 1:1:1 1:2:2 1:1:1 1:2:2 1:1:1 1:2:2 
Current 
(A) 
1.2553 2.0726 0.8037 1.1171 0.7724 1.6919 
Sensitivity 
(A/mM) 
1.7222 2.6139 1.1929 1.5097 1.1404 2.2810 
R
2
 0.9929 0.9860 0.9795 0.9891 0.9745 0.9947 
SD 0.5976 0.7680 0.4357 0.4471 0.3843 0.6873 
Detection 
range (mM) 
0.10 – 0.90 0.00 – 0.75 0.10 – 0.90 0.05 – 0.75 0.00 – 0.90 0.05 – 0.75 
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Each experiment was done in at least duplicates; the current shown in the tables is the average of 
2 readings. Each electrode was also validated with 0.30 mM and 0.60 mM OA as shown in green 
on the calibration graphs below (Figure 4-21 and Figure 4-22). This shows all the electrodes 
have reproducibility. Validation was done in the same way as that described for Figure 4-13, in 
total 4 electrodes were used for each graph - 2 for the measurements shown in green and 2 for 
the measurements shown in black. 
 
Figure 4-21: Calibration graph obtained by LSV of various concentrations of OA on a CoPc-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4 and 1 mM ATP and CoA, scan rate 1 mV s
-1. 
 
Figure 4-22: Calibration graph obtained by LSV of various concentrations of OA on a SWCNT SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4 and 2 mM ATP and CoA, scan rate 1 mV s
-1. 
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4.3.3 Multiple Layer comparison of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS) 
electrode 
CA of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 and (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)4 electrodes were spiked with 0.25 mM OA (shown in Figure 4-23).   The set 
potential was 500 mV for each electrode. 125 L of 1 mM Wako OA standard solution was 
added to phosphate buffer solution containing 1 mM CoA and ATP at ~500 s, making the result 
of OA concentration at 0.25 mM. There was no time delay observed from both electrodes. Once 
OA was spiked, an instant current increase was obtained. This implies that the immobilization 
method produced fine thickness of polymer-bienzyme layers. These layers did not affect the 
mass transport of reactants cascading down the layers to fulfil two-step enzymatic reactions in 
sequence. The thickness of each layer has previously found to be 1-2 nm [331].  
 
The higher the amount of bienzyme layers, the higher the current produced, as the amount of 
enzymes (ACS and ACOD) were quadrupled in (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)4 
compared to (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1. One unit of ACOD enzyme 
activity is defined as the amount of the enzyme which produces 1 mol H2O2 per min [270]. So 
naturally using less enzyme results in having less H2O2 production in (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 when compared to (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)4.  
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Figure 4-23: CA (E = 500 mV) of OA spiking on  (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 as black line and (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)4 as blue line,  in 0.1 M phosphate buffer pH 7.4 and 1 mM ATP and CoA. The 
concentration of OA before and after the spike is 0 mM and 0.25 mM, respectively. 
 
 
However the amount of current produced was not directly proportional to the number of layers. 
Table 4-5 compares the current changes at 10 s and 100 s after spiking of OA on both electrodes. 
The current increases for one layer were 178 % at 10 s and 97.2 % at 100 s, respectively; for 
four-layer were 220 % and 99.8 %. The increase in current from both electrodes at 10 s and 100 s 
was similar, although the change on the four-layer electrode was slightly higher, but not 
proportionally as high as the amount of enzymes on the electrode (4 times higher). 
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Table 4-5: Comparison between (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 and (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)4 electrodes with OA spiking. 
Time after 
OA added 
(s) 
(PDA-
MWCNT/ACOD/PDA-
MWCNT/ACS)1 (A) 
Current 
difference 
with 0 s (%) 
(PDA-
MWCNT/ACOD/PDA-
MWCNT/ACS)4 (A) 
Current 
difference 
with 0 s (%) 
0 0.1492 - 0.1920 - 
10 0.4153 178 0.6140 220 
100 0.2942 97.2 0.3836 99.8 
 
The electrochemical activity is not expected to increase linearly with the number of enzyme 
layers [333]. Rendering to the electron transfer theory, with increasing layers there is increasing 
distance from the electrode, the second layer plus of enzyme may not have its whole 
electrochemical activity. Another thing is thicker layers may increase electron-hopping distance 
and hinder diffusion of the supporting electrolyte [330]. So for future detection of NEFA the 1 
layer of bienzyme electrode seems more practical and feasible for NEFA biosensor development, 
as it takes less time to make and does not use as much enzyme. 
 
4.3.4 Confirmation of multiple layer configuration 
EIS measurements were used to monitor the changes in charge transfer resistance (Rct) during the 
assembly of the multilayer films for the bilayer electrode only (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) during the modification process. The selection of 0.17 V is due to it being near 
the equilibrium of reductive and oxidative rates of the K3[Fe(CN)6] : K4[Fe(CN)6] pair, and so 
that the redox species would not deplete near the electrode surface during the impedance 
measurements [309]. Measurements of the phase difference and the amplitude (i.e. the 
impedance) permits analysis of the electrode process in relation to contributions from diffusion, 
kinetics, double layer and/or coupled homogeneous reactions [251]. Figure 4-24 shows a 
strongly adsorbed intermediate in the absence of mass transport control. The Nyquist plot has 
two areas of interest, the high frequency region (electron-transfer properties) and the low 
frequency region (electrolyte diffusion controlled properties) [255, 334]. The semi-circle is 
related to the electron charge transfer resistance (RCT). This resistance controls the redox probes 
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electron transfer kinetic process at the electrode interface [309]. The smaller it is the more 
conductive is the electrode or the materials used to modify the electrode. The RCT depends on the 
dielectric and insulating features at the electrode/electrolyte interface [335]. As the number of 
bilayers increased so did the electron charge transfer resistance, from 2.31 K Ω (bare electrode) 
to 3.89 K Ω (1 bilayer) to 4.01 K Ω (2 bilayers) to 4.06 K Ω (4 bilayers), confirming step-wise 
assembly of the multi-layer films due to the polymer and enzyme deposition as shown in Table 
4-6. The solution transfer resistance remained the same. 
 
Figure 4-24: The Nyquist plots of C-SPE modified for:  bare C-SPE; (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1; 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS)2 and (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)4, all in 5 mM 1:1 
mixture of K3[Fe(CN)6] : K4[Fe(CN)6] at an applied voltage of 0.17 V. 
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Table 4-6: Properties determined by EIS of different enzyme layers. 
Enzyme layer 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) 
0 1 2 4 
Charge transfer resistance 2.31 k Ω 3.89 k Ω 4.01 k Ω 4.06 k Ω 
Solution transfer resistance 235 Ω 236 Ω 243 Ω 243 Ω 
Capacitance 34.1 F F F F 
 
LSV was done to confirm that having multiple layers shows as having more enzyme 
immobilized on the electrode. The normal ACS peak that was found at around 350 mV in Figure 
4-9 is shown as being around 300 mV in Figure 4-25, this is for the electrode (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1, however the same peak shifted to a more negative 
potential in (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)4 at around 140 mV. Adding 0.25 mM 
OA to each electrode showed a substantial increase in current for the electrode (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)4, supporting the fact that more enzyme is there so more 
H2O2 oxidation can happen rapidly. Increasing the film thickness did not increase the difficulty 
for OA to diffuse through the film. At 500 mV the current produced for (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 was 0.0146 A compared to that of (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)4 which was 0.4294 A (both background subtracted). 
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Figure 4-25: LSV at 1 mV s-1 showing (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 as black line and (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)4 as purple line,  in 0.1 M phosphate buffer pH 7.4 and 1 mM ATP and CoA. The 
same electrode with 0.25 mM OA is then shown as the dashed line respectively. 
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4.3.5 Use of N-ethyl-maleinimide and effect of excess CoA 
In some optical commercial methods of NEFA detection, the compound N-ethyl-maleinimide 
(NEM) is added to remove excess CoA, as the presence of non-reacted free CoA inhibits the 
reaction with POD, the sulfhydryl group of any remaining CoA is blocked with NEM after the 
first step [132]. 
Unreacted CoA + NEM  CoA-NEM 
The company Roche Applied Science for example adds 50 L of NEM solution (this is the same 
volume of plasma/serum in the reaction), stating that NEM is necessary for the ‘removal of an 
existing surplus of CoA’ before the oxidation of the activated fatty acids by ACOD [336]. Whether or 
not NEM is needed in the electrochemical method, and what the excess amount of CoA is, needs 
to be investigated.  
Two bienzyme electrodes of (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 were fabricated at 
the same time and tested with 0.10 mM OA at a 1:2 molar ratio with 0.20 mM CoA and at a 1:20 
molar ratio with 2.00 mM CoA. 0.10 mM OA was selected as it is the lowest amount of NEFA 
detectable on the electrode, so its response to excess CoA would aid in the investigation without 
using too much substrate. Figure 4-26 shows the LSV at 1 mV s
-1
, with ATP having the same 
molar ratio as CoA, in PBS. 
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Figure 4-26: LSV for 0.10 mM OA measured on two C-SPE’s modified with (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)1 (one electrode shown in green and one electrode shown in red) in 0.1 M phosphate buffer pH 7.4, scan 
rate 1 mV s-1. 
 
Excess CoA meant that more H2O2 could be produced and detected electrochemically. 20 times 
higher CoA ratio produced 0.7569 A compared to 0.0005 A at 1:2 molar ratio, at the potential 
of 500 mV. When the concentration of CoA was 0.20 mM, there was not substantial H2O2 
production, concluding that excess CoA is needed in order for the reaction to occur. 
However the LSV for both the electrodes in 0.00 mM OA shows a very different profile and 
current production at 500 mV. A solid conclusion with regards to having excess CoA or not 
cannot be drawn from this data alone. More repeats are needed. 
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The effect of NEM electrochemically in the enzyme reaction was investigated via 
chronoamperometry by adding 5.25 L NEM (same volume ratio as that in Roche optical 
method) to 120 L of total solution containing 0.10 mM OA, ATP, CoA and PBS (Figure 4-27). 
Firstly 0.10 mM OA was detected at each electrode, followed by the addition of NEM. At 500 s 
1:20 showed a 0.0801 A reduction in current, whereas 1:2 showed a 0.0729 A reduction. 
Addition of NEM did not increase the amount of H2O2 detected, both the molar ratios showed 
similar reduction in current, concluding that NEM is not needed for the electrochemical detection 
of NEFA. 
 
Figure 4-27: CA (E = 500 mV) of OA with and without NEM on (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 at 
different molar ratios of CoA and ATP. All background subtracted. 
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4.3.6 Stability 
The stability of the electrode was tested by immobilizing four different enzyme electrodes (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 at the same time (Figure 4-28). The electrodes were 
stored under the same conditions (in PBS at 4 
o
C).  
 
 
Figure 4-28: Set-up for 4 C-SPE’s immobilized at the same time. 
One electrode was tested at each period (via chronoamperometry at 500 mV) using 0.00 mM OA 
and 0.75 mM OA. All the tests contained PBS, 1 mM ATP and 1 mM CoA. The electrodes were 
tested on four different days (on the day of fabrication, 1 day, 3 days and 6 days later).  Between 
the tests the electrodes were stored in the cell with the last layer of enzyme still fabricated on, 
therefore the electrodes were stored wet. They were rinsed with PBS as usual to remove the 
excess unbound enzyme and polymer, before the experiment was done. The data is shown in 
Table 4-7. The ‘current difference’ was worked out by the current produced at 0.75 mM OA 
minus the current at 0.00 mM OA for each day. The ‘percentage difference from day 0’ was 
worked out by the current difference on the other days divided by the current difference of day 0 
(0.4139 A). After 1 day, the electrode lost 2 % activity. The electrode was stable for 3 days 
(retaining over 90 % activity), beyond which the enzymes had lost activity and denatured 
(resulting in a negative reading for current difference at day 6). 
 
Table 4-7: Chronoamperometry at 500 mV, readings taken at 500 s. 
Day 
(at 500 s) 
Current (A) 
for 0.75 mM 
Current (A) 
for 0.00 mM 
Current (A) 
difference 
% difference 
from day 0 
0 0.6900 0.2761 0.4139 - 
1 0.4664 0.0610 0.4054 2.05 
3 0.8452 0.4675 0.3777 8.75 
6 2.9601 5.0308 -2.0707 600 
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4.3.7 Reproducibility 
The reproducibility of the electrode was tested by CA of one fabricated electrode with the 
concentration of 0.00 mM OA and 0.75 mM OA on the day of fabrication and 1 day later. The 
electrode was stored wrapped in foil in the fridge at 4 
o
C over night. The electrode was rinsed 
with PBS before the re-run. Figure 4-29 shows the chronoamperometric comparison of the same 
electrode 1 day after fabrication and use. The response dropped to that below 0.00 mM OA. 
Therefore the enzyme fabricated electrode is not re-usable the next day. Most commercially 
available sensors have disposable one use only electrodes. The same would apply for electrodes 
for NEFA detection.  
 
Figure 4-29: CA (E = 500 mV) of 0.75 mM OA (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 electrode in 0.1 M 
phosphate buffer pH 7.4 with 1 mM ATP and CoA. 0.00 mM OA consisted of 0.1 M phosphate buffer pH 7.4 with 1 mM 
ATP and CoA only. 
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4.3.8 Determination of OA using (PDA/ACOD/PDA/ACS) fabricated electrode 
The use of CNT in the immobilization of ACS and ACOD may not be necessary as there is no 
redox activity of the enzymes, unlike in glucose sensors (using GOx) which rely on CNT to 
shuttle electrons. The enzyme electrode (PDA/ACOD/PDA/ACS)1 was fabricated and tested 
with OA concentrations on C-SPE. LSV at 1 mV s
-1
 is shown in Figure 4-30. The calibration 
graph compared with the previously fabricated bienzyme electrode (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 is shown in Figure 4-31, as can be seen, there was more 
linearity established with using CNT than without (higher R
2
 value). Although the current 
produced without CNT is slightly higher, for the purpose of the sensor, CNT will be taken 
forward. Both the fabricated electrodes had the same linear detection range of 0.10 – 0.90 mM 
OA. 
 
Figure 4-30: LSV of various concentrations of OA measured at a C-SPE modified with (PDA/ACOD/PDA/ACS)1 in 0.1 M 
phosphate buffer pH 7.4 and 1 mM ATP and CoA, scan rate 1 mV s-1. 
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Figure 4-31: Comparison of calibration graphs at 500 mV of LSV’s obtained from (PDA/ACOD/PDA/ACS)1  in black 
and (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 in blue on C-SPE. 
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4.3.9 Interferences 
The effects of these interferences needed to be investigated to further the development of the 
NEFA biosensor. The enzyme fabricated electrode was tested individually with urea (3 mM), 
uric acid (8 mM), ascorbic acid (0.5 mM), glucose (10 mM), albumin (0.6 mM), paracetamol 
(120 M) and aspirin (3 mM), in a similar manner to that described in section 3.3.5. The reasons 
behind investigating these interferences, is the same as those given in that section. 
LSV and CA (at 500 mV) were carried out for each interference, using 0.25 mM OA as the 
reference to compare the current to. Table 4-8 shows the sensitivity, correlation coefficient (R
2
), 
detection range and percent interference for each compound studied. The detection range given 
here is the linear detection range in which the compound was detectable during the CA at 500 
mV. The compounds with very low sensitivity (urea, glucose, aspirin and albumin) may not be 
fully detectable on the enzyme fabricated electrode. 
Table 4-8: Each interference at 500 s CA at 500 mV. 
Compound 
Sensitivity 
(A/mM) 
R
2
 
Detection 
range (mM) 
% interference 
with 0.25 mM OA 
Comparison to 
work in solution 
Urea - 0.0037 0.5387 0.5 – 10 -28.3 Up 
Uric acid 1.3106 0.9931 0 – 8 5004 Down 
Ascorbic acid 2.6352 0.9787 0.1 – 1.0 1497 Up 
Glucose - 0.0009 0.846 2 - 30 27.2 Down 
Acetaminophen 1.5325 1.000 0 – 0.12 938 Up 
Aspirin - 0.0807 0.4039 1 - 3 -15.5 Down 
Albumin - 0.0491 0.7111 0.2 -0.6 2 Down 
 
Looking at the table, 4/7 of the interferences were reduced with the immobilized electrode when 
compared to the work in solution. As expected uric acid, ascorbic acid and acetaminophen 
showed the highest interference, as they are readily oxidizable compounds. However the 
interference from uric acid had decreased over 3 fold with the enzymes immobilized.  
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Chronoamperometric response at 500 mV of uric acid on the modified electrode is shown in 
Figure 4-32. Above 5 mM uric acid, the electrode was unable to detect increasing concentrations 
of uric acid. In human plasma, uric acid is one of the most important kidney calculus indices 
[337]. So this will most definitively be present in blood detection of NEFA. 
 
 
 
 
 
 
The electrode surface has been fouled by the oxidation product of uric acid, this is shown by the 
CV in Figure 4-33. Only the first concentration (1 mM) gave the usual voltammetric peak at 200 
mV. All the other concentrations of uric acid gave a peak which showed the electrode surface 
had been fouled. This would mean that uric acid would interfere with the NEFA detection, as it 
would block the site on the C-SPE, where H2O2 would be oxidised. Each fabricated electrode 
would be usable once. 
Figure 4-32: CA at 500 mV for various concentrations of Uric acid measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4. Inset: Calibration graph at 500 s. 
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Figure 4-33: CV of various concentration of uric acid at scan rate of 5 mV s-1 using a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4. 
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The chronoamperometric response at 500 mV of ascorbic acid on the modified electrode is 
shown in Figure 4-34. Linear response was obtained up to 1 mM ascorbic acid. 
 
 
 
 
 
 
A (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 electrode was fabricated and 1 mM 
ascorbic acid was added into the solution containing; PBS, 1 mM ATP and 1 mM CoA. The 
electrode was tested with varying concentrations of OA. The barchart in Figure 4-35 gives the 
comparison of the current response (500 s) of CA at 500 mV with ascorbic acid in the solution 
compared with the data from Figure 4-14. Excluding the reading of 0.25 and 0.50 mM OA, 
ascorbic acid is predicted to be an interference in the study in blood, in some cases by giving 
two fold higher current (0.10 and 0.90 mM OA). This is still not as high as that was was 
predicted in Table 4-8. This experiment was only done once. There is no systematic increase 
in current production with the same concentration of ascorbic acid (1 mM) and varying 
Figure 4-34: CA at 500 mV for various concentrations of Ascorbic acid measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4. Inset: Calibration graph at 500 s. 
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concentrations of OA. This experiment shows that the current production at 500 mV will 
fluctuate when ascorbic acid is in solution with the fabricated electrode. 
 
 
Figure 4-35: Barchart of current obtained at 500 s of CA at 500 mV for 1 mM ascorbic acid added in as interference  
measured at a C-SPE modified with (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4, 1 
mM ATP and CoA with varying concentrations of OA. 
 
 
 
Chronoamperometric response at 500 mV of acetaminophen on the modified electrode is shown 
in Figure 4-36. The oxidation of acetaminophen was linear for concentrations up to 0.12 mM 
acetaminophen. The subsequent LSV is shown in Figure 4-37. There is a profound oxidation 
peak present with acetaminophen, which increases as the concentration increases. This would 
interfere with H2O2 oxidation at 500 mV. Therefore is a problem for NEFA detection. 
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Figure 4-37: LSV of various concentrations of acetaminophen  measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4, scan rate 1 mV s
-1. 
 
 
Figure 4-36: CA at 500 mV for various concentrations of Acetaminophen measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4. Inset: Calibration graph at 500 s. 
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On a new fabricated electrode, 5 mM glucose was added into the solution and tested with the 
bienzyme electrode with varying concentrations of OA. The barchart below (Figure 4-38) gives 
the comparison of the current response (500 s) of CA at 500 mV with glucose (present as an 
interference)  in the solution compared with the data from Figure 4-14. For the higher 
concentrations of OA (0.50 mM OA plus), glucose showed a 7 % plus increase in current. 
Meaning it would interfere in NEFA detection. 
 
Figure 4-38: Barchart of current obtained at 500 s of Chronoamperometry at 500 mV for 5 mM glucose  added in as 
interference,  measured at a C-SPE modified with (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate 
buffer pH 7.4, 1 mM ATP and CoA with varying concentrations of OA. 
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4.4 Conclusions  
 
In this chapter many enzyme electrodes were fabricated using LbL method on different SPE (C-
SPE, CoPc and SWCNT SPE). Firstly, the (PDA-MWCNT/ACOD)2 fabricated electrode was 
made and tested with concentrations of OA-CoA and PA-CoA (up to 1.5 mM). Then the 
bienzyme electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 was fabricated and various 
concentration of OA were tested (up to 0.90 mM). Linear calibration graphs of LSV at 500 mV 
(with R
2
 of ~0.99) and CA at 500 s at 500 mV chosen potential (with R
2
 of ~0.99) were obtained 
and will be used as the reference graphs for future comparisons. The linear detection range of 
OA was found to be 0.10 mM to 0.90 mM. Multiple layer comparison and confirmation was 
done using the electrochemical techniques of CA, EIS and LSV. 
Other similar fabricated electrodes were also made and tested with the same concentration of OA 
as a reference, these electrodes were (PDA-MWCNT/ACS/PDA-MWCNT/ACOD)1 and (PDA-
MWCNT/ACOD+ACS)1. These electrodes had lower linear detection ranges, so were not to be 
taken forward in NEFA sensor development. 
The molar ratio of ATP and CoA was also investigated on all 3 SPE (C-SPE, CoPc and SWCNT 
SPE) for the fabricated enzyme electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1. 1:1:1 
molar ratio was found to be sufficient for linearity and reproducibility of this work. The use of 
NEM and effect of excess CoA was also investigated as literature stated they would be a problem 
for NEFA detection. This was invalid for electrochemical NEFA detection. The stability of the 
electrodes was up to 3 days. There was no reproducibility found for re-using the same enzyme 
fabricated electrode the next day. 
The C-SPE (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 enzyme electrode was taken forward 
and tested with common interferences that would be present in blood. This data was a 
comparison with that in the previous chapter. 
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5 Enzyme fabricated electrodes for blood NEFA detection 
5.1.1 Introduction 
This section will look at fabrication of the electrode to keep common interferences in blood to a 
minimum. A schematic of what should be happening in each layer of the LbL fabricated 
electrode is illustrated in Figure 5-1. The last layer, should not only reduce the likelihood of 
biofouling, but also regulate the diffusion of NEFA [338]. The outer membranes role is 
particularly important in sensor function [229]. The desired role of the last layer is shown in the 
figure below. It should hypothetically allow the diffusion of O2, CoA, ATP and NEFA, but 
withhold the penetration of interferences such as ascorbic acid, uric acid and acetaminophen. 
 
Figure 5-1: Various chemical, electrochemical and diffusion processes on the LbL electrode of the current NEFA sensor. 
Adapted from [338]. 
 
Figure 5-2 shows chemical structures of common polymeric materials [216]. These can be 
incorporated in the current LbL configuration (as the last layer) to attempt to reduce interferences 
that would be present in blood. 
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Figure 5-2: Chemical structure of commonly used polyelectrolytes. 
 
Immobilization usually perturbs the microenvironment of the active site of the enzyme, resulting 
in alterations of the enzymes intrinsic kinetic characteristics [322]. Alkaline shifts could be due 
to negatively charged surface or a loss of positive charge on the enzyme because of the 
immobilization procedure. An acidic shift may be caused by positively charged surface or 
negative charge lost on enzyme, or both reasons combined.  
 
 
 
123 
 
5.1.2 Experimental 
5.1.2.1 Materials 
Roche free fatty acids, Half-micro test assay kit (cat no. 11 383 175 001) was purchased from 
Roche Applied Science (West Sussex, UK). The Wako HR series NEFA-HR (2) kit was 
purchased from Wako Diagnostics (Neuss, Germany). Oleic acid (OA) was the Wako NEFA 
standard solution used again in this work. 
Serum and plasma samples were kindly donated by Newcastle University Medical School, from 
Professor Mike Trenell’s group. Blood samples were collected by a cannula inserted into a 
forearm vein. Blood samples were spun in a centrifuge (Harrier 18/80R; MSE Ltd, London, UK) 
for 10 minutes at a speed of 3000 rpm at 4 
o
C. Plasma was then pipetted off each sample and 
stored at -40 
o
C. The samples were then stored at -80 
o
C until use. Once the centrifugation was 
complete and even after storage, the serum/plasma samples needed to be checked for haemolysis 
[339]. If there was any obvious haemolysis those samples were discarded, all samples are shown 
in Figure 5-3. 
 
Figure 5-3: Samples of serum and plasma (some haemolysed). 
Poly [2-methacryloyloxyethyl phosphorylcholine – co-n-butyl methacrylate – co-p-
nitrophenyloxycarbonyl poly(ethylene glycol) methacrylate] (PMBN) 5 % solution in ethanol 
was provided by Dr. Yu (structure is shown later in Figure 5-10). This was made by the method 
described in work done by Konno et al. [340]. It was prepared by random copolymerization of 2-
methacryloyloxyethyl phosphorylcholine (MPC), n-butyl methacrylate and p-nitrophenylester 
bearing methacrylate. 
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Bovine serum albumin (BSA) was purchased from Sigma Aldrich (Dorset, UK). BSA solution 
consisted of 1 mM BSA concentration in PBS. Sodium poly(styrenesulfonate) (PSS) was also 
purchased from Sigma Aldrich (Germany). Poly(methacrylic acid sodium salt) (PMAA) was 
purchased from Polysciences Inc (Eppelheim, Germany). Both polymer solutions consisted of 1 
% polymer in solution, with 0.20 M NaCl in 5 mL distilled water. 
 
5.1.2.2 Optical measurements 
The UV spectrophotometer used was Ultrospec 3000 (Pharmacia Biotech). The Roche protocol 
titled ‘Free fatty acids, Half-micro test’, was used to obtain a calibration graph with OA Wako 
NEFA standard solution 1 mM with N-ethyl-maleinimide (NEM) [142]. The different OA 
concentrations were made by diluting the standard 1 mM OA standard solution with double 
distilled water. Each run was done in triplicates and then averaged. 6 plasma samples were then 
tested optically, and the concentrations of NEFA were determined by reading against this 
calibration graph obtained by using OA standard.  
The Wako protocol was used for the rest of the serum/plasma samples [143]. The unknown 
blood samples were read-off against the calibration graph obtained using OA standard. 
Both optical methods were validated with 0.30 mM and 0.60 mM OA, made up in the same 
manner but ran separately to the bulk OA concentrations (Figure 5-4 and Figure 5-5). The figure 
shows the great level of reproducibility and linearity obtained from the current optical method. 
 
Figure 5-4: Optical validation. Concentrations 0.00 mM to 0.90 mM OA from left to right respectively. Far right 
concentrations 0.30 mM and 0.60 mM OA. 
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Figure 5-5: Calibration graph obtained by measurement of various concentrations of OA by the Roche colorimetric 
method. The fitting is based on average values obtained from three measurements (=546 nm). 0.30 mM and 0.60 mM 
were measured independently (shown in green).   
 
5.1.2.3 Electrochemical measurements 
Each experiment was first done with the individual fabricated electrode with various 
concentration of Wako OA standard (0.00, 0.10, 0.25, 0.50, 0.75 and 0.90 mM). Once this 
calibration graph was obtained, then the serum/plasma experiments were done and compared to 
this calibration graph. 
Fabrication of electrodes 
The (PDA/ACOD/PDA/ACS)1 electrode was fabricated in the same way as described in section 
4.1.3. The rest of the specific electrodes were fabricated following adaptation from the original 
electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1. 
The PMBN fabricated electrodes consisted of 8 L of PMBN 5 % solution in ethanol. This was 
deposited directly on the WE of the C-SPE after the original fabrication, forming a gel-like layer 
as shown in Figure 5-6. The experiments were done with either 1 mM ATP and 1 mM CoA 
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mixed into the PMBN layer (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PMBN+ATP+CoA)1 
or without (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PMBN)1. 
 
Figure 5-6: Electrode with PMBN layer. 
 
The (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/BSA)1 electrode was fabricated following the 
original protocol, then depositing 10 L of BSA solution. Although BSA has been listed as 
interference in the UV method, it is used as an outer membrane layer in other glucose sensor 
work, which is why it was incorporated into this sensor too. 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PSS)1 and (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PMAA)1 were fabricated as the original 
electrode, then 15 L of PDA-MWCNT solution, then 15 L of PSS/PMAA solution was 
deposited. These polymers were chosen because at pH 7.4, both of these polymers would have a 
negative charge, as their isoelectric point is below that of the pH. As negatively charged 
polymers they would be able to electrostatically bind to the positively charged PDA-MWCNT 
layer and in theory reduce interference. 
Each electrode was left in the fridge after each additional step (for 30 minutes) and washed with 
PBS before the next step. 
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5.1.3 Serum vs. plasma 
The decision between collecting and testing in plasma or serum is based on the distinctive 
requirement that the sample is needed for. Table 5-1 states the advantages and disadvantages of 
one over the other. For this study both serum and plasma samples were analysed. Firstly plasma 
was used, but as plasma contains fibrinogens, which are thought to affect the electrochemical 
measurements, serum samples were used as they were thought to be more ‘cleaner’.  
Table 5-1: Advantages and disadvantages of plasma over serum [341]. 
Advantages of plasma over serum Disadvantages of plasma over serum 
Quicker process – the wait for blood to clot is 
eliminated 
Method-dependent interference from 
anticoagulants 
Higher yield – from whole blood ~15-20 % 
more plasma than serum will be attained 
Cation interference – lithium/ammonium might 
increase due to contamination with heparinates 
usage 
Essentially no interference from the 
postcentrifugal coagulation that happens in 
serum 
Fibrinogen changes protein electrophoresis 
results 
In vivo is more representative from plasma 
results than serum 
 
Reduced chance of haemolysis and 
thrombocytolysis 
 
 
5.2 Detection of plasma samples  
Six different plasma samples (from different patients) were tested optically with the commercial 
Roche kit, the NEFA concentrations were read against the calibration graph obtained in Figure 
5-5. The respective NEFA concentration in plasma came to 0.15 mM, 0.23 mM, 0.25 mM, 0.31 
mM, 0.35 mM and 0.53 mM. The same plasma samples were then tested electrochemically using 
the enzyme fabricated electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 and compared 
to the calibration graph previously obtained in Figure 4-14 in Figure 5-7 (data taken from 500 s). 
A comparison of the values obtained is shown in Table 5-2. The NEFA value obtained 
electrochemically was at least twice as high as that compared to the optical method in five out of 
the six samples. This is due to the multiple interferences in human plasma. However the 
interference from blood is not as high as what was predicted from the interference study in 
section 4.3.9, where individual concentrations of each interference were tested on the fabricated 
electrodes (e.g. 8 mM uric acid). 
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Figure 5-7: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4, with 1 mM ATP and CoA (in black) along with 
6 plasma concentrations measured independently in duplicates (in red).   
Table 5-2: Comparison of the NEFA values obtained in 6 plasma samples from the two different detection methods. 
Concentration using 
optical method (mM) 
Concentration using 
electrochemical method (mM) 
0.15 0.900 
0.23 0.725 
0.25 1.190 
0.31 0.890 
0.35 0.875 
0.53 0.700 
 
5.3 Detection of serum samples 
Figure 5-8 shows the chronoamperometric results for serum samples run at 500 mV for the 
fabricated electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1. The calibration graph in 
Figure 5-9 shows the results from CA at 500 s (from Figure 4-14), along with those of 5 serum 
samples run from the two patients. The UV concentrations of 0.114, 0.122, 0.171, 0.342 and 
0.513 mM came to 0.70, 0.85, 0.50, 0.76 and 1.05 mM electrochemically. This is a 514, 597, 
192, 122 and 105 % increase respectively. The lower the concentration of NEFA was the higher 
the increase in current due to interference. However both plasma and serum did not give 
consistent/reproducible NEFA concentrations. The electrode now needs further fabrication, as 
shown in Figure 5-1 earlier. 
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Figure 5-8: CA at 500 mV for various concentrations of serum NEFA (from 2 patients) measured at a C-SPE modified 
with (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4. 
 
Figure 5-9: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 0.1 M phosphate buffer pH 7.4, with 1 mM ATP and CoA (in black) along with 
5 serum concentrations (in red).   
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5.4 Comparison of different fabricated electrodes performance using human blood 
After using plasma and serum samples, the interference detected on the (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS) electrode is high, as expected. However, it is not as high 
as was predicted from the interference work done on the fabricated enzyme electrode in section 
4.3.9. In order to make a commercial biosensor for blood NEFA detection, the sensor needs to 
work in blood in a reliable and reproducible manner. To do this the current enzyme electrode 
needs further fabrication to reduce the interferences. The last layer as shown in Figure 5-1 needs 
to be incorporated.  
Table 5-3 shows the CA data at 500 mV for the various fabricated electrodes, and the current for 
0.90 mM OA at 500 s, the percentage difference was worked out by using current from the 
standard (PDA-MWCNT/ACOD/PDA-MWCNT/ACS) electrode as the reference (data shown in 
Figure 4-15). The individual CA for each electrode and their calibration graphs at 500 seconds 
are given in the appendix (in Figure 7-6 to Figure 7-17), along with some explanation of the 
actual result produced. 
Table 5-4 shows the respective LSV at 1 mV s
-1 
for each electrode, the current for comparison is 
at 500 mV for 0.90 mM OA. The reference data for the LSV comparison was taken from Figure 
4-10. 
The different electrodes fabricated contained either PMBN (results shown in appendix as Figure 
7-8 to Figure 7-11) or BSA (Figure 7-12 and Figure 7-13) as the last layer after (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS) or the polymers PSS or PMAA (shown in Figure 7-14 to 
Figure 7-17) after (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT). The LbL 
fabrication of electrodes had an additional PDA-MWCNT layer for the negatively charged 
polymers PSS and PMAA because the PDA-MWCNT layer is positively charged. Each 
fabricated electrode was tested with the various concentrations of OA, and then a new electrode 
was fabricated for the different blood samples. 
From both the tables (hence both the methods CA and LSV), using PMBN gave the best results 
when compared to the standard bienzyme electrode (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS)1. This was the only method that did not rely on LbL deposition but was instead 
a gel-like layer on top of the pre-immobilized LbL enzyme electrode. The phospholipid polymer, 
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(poly [2-methacryloyloxyethyl phosphorylcholine (MPC) – co-n-butyl methacrylate (BMA) – 
co-p-nitrophenyloxycarbonyl poly(ethylene glycol) methacrylate (MEONP)]) (PMBN) has 
positively charged groups that bind electrostatically to negatively charged groups [342]. PMBN 
is a deacylated derivative of polymyxin B (PMB), which is a polycationic drug. Structure of 
PMBN is shown in Figure 5-10, it consists of three polymer chain segments. 
 
Figure 5-10: Chemical structure of water-soluble PMBN polymer [343, 344]. 
The outer layer of PMBN contains polar phosphorylcholine group, this suppresses non-specific 
adsorption of particular proteins (BSA and -globulin) [345]. The orientation of these groups at 
the external surface of the bilayer, gives a neutral, zwitterionic interface, having little or no 
attraction for proteins on the extracellular environment. 
 
MPC polymers have acted as surface modifiers to improve biocompatibility in several medical 
devices [346]. The active ester group in the MEONP side chain makes PMBN conjugate to any 
material containing ester bonds. PMBN is known to maintain its enzyme activity [343]. PMBN 
has good biocompatibility, inhibiting the adhesion and activation of blood cells, resulting in it 
reducing blood coagulation when in contact with blood [343]. So incorporating PMBN into the 
enzyme electrode could help reduce the interference with blood, yet maintain PMBN’s activity. 
The electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PMBN+ATP+CoA) had ATP and 
CoA incorporated into the PMBN layer, this electrode gave the lowest interference with blood 
(+14 %) compared to the electrode that had ATP and CoA in solution (+78 %). 
  
Another electrode of interest was the (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/BSA)1 
fabricated electrode which gave 64 % plus interference. Human serum albumin (HSA) and BSA 
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have approximately 76 % sequence homology, with a similar three-dimensional structure [347]. 
BSA is a single polypeptide chain with around 583 amino acid residues and no carbohydrates 
[299, 300, 348]. At the pH range of 5-7 it comprises of 17 intrachain disulfide bridges and only 1 
sulfhydryl group (free thiol), positioned in a repeating series of 9 loop-like structures centred on 
8 sequential cys-cys pairs [349]. Albumins contain an excess of amino acids [350]. Serum and 
plasma albumin comprises of 55-62 % of the protein present. 
BSA is used in biosensor fabrication because it is inert, lysine rich and inexpensive, and makes 
films more stable and sensitive [351]. It has a strong affinity for various types of surfaces and 
does not interfere in many biochemical reactions [349]. 
 
Molecular interactions between NEFA and plasma albumins from various species can have 
differences [352]. Studies by Spector et al. have been done to compare NEFA binding to human, 
bovine and rabbit albumin [303]. Results for palmitate showed a small difference in the binding 
constants (bovine > rabbit > human). To human albumin laurate and oleate were bound more 
tightly than to bovine albumin [352]. Hydrophobic interactions are responsible for the binding 
energy for fatty acids binding to albumin. The BSA fabricated electrode had +64 % interference 
in plasma when compared to the electrodes performance with the OA standard. 
 
The PMAA based fabricated electrode gave the lowest current (highest difference compared to 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 electrode), and its interference was so high that 
it was unreadable off the graph (shown in Figure 7-17 in the appendix), this was because PMAA 
was the weakest polyelectrolye used (pKa = 6-7), so its attraction was not as strong as the other 
polyelectrolytes. Its carboxylic acid groups degree of ionization depends on the pH [353]. There 
is significant influence on the complex that is formed of the interacting polymer with its nature 
and molecular weight [354]. Environmental factors such as the solvent (it is in), pH, ionic 
strength, temperature and polymer concentration also play a part. Poly[(meth)acrylic acid]s make 
interpolymer complexes with: 
 Non-ionic proton accepting polymers and their derivatives 
 Cationic polyelectrolytes in media (aqueous and organic) 
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Table 5-3: Electrode comparison for CA at 500 mV, current taken at 500 s. 
Electrode fabrication 
Sensitivity 
(A/mM) 
R
2
 
value 
Linear 
detection 
range 
(mM) 
Current 
for 0.90 
mM 
OA 
(A) 
% difference with 
(PDA-
MWCNT/ACOD/PDA-
MWCNT/ACS) 
Tested with 
plasma/serum 
Sensitivity 
(A/mM) 
R
2
 
value 
% 
interference 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) 
 
0.6562 0.9883 0.1 – 0.9 0.7480 - 5 serum  1.1514 0.9974 105 % + 
(PDA/ACOD/PDA/ACS) 
 
1.4969 0.9620 0.1 – 0.9 1.3543 81 4 serum  3.7640 0.9864 16.8 % + 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PMBN) 
 
0.8335 0.9516 0.1 – 0.9 0.8089 8 5 plasma 0.1149 0.3358 78 % + 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PMBN+ATP+CoA) 
 
0.8613 0.9464 0.1 – 0.9 0.8557 14 5 plasma -0.6584 0.5083 14 % + 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/BSA) 
 
0.6790 0.9510 0.1 – 0.9 0.5985 -20 5 plasma 0.3904 0.3562 64 % + 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PDA-
MWCNT/PSS) 
 
0.4810 0.9639 0.1 – 0.9 0.4192 -44 4 serum  1.4308 0.9474 208 % + 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PDA-
MWCNT/PMAA) 
0.2571 0.9108 0.1 – 0.9 0.2588 -65 4 serum  1.6474 0.9922 - 
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Table 5-4: Electrode comparison for LSV at 1 mV s-1, current taken at 500 mV. 
Electrode fabrication 
Sensitivity 
(A/mM) 
R
2
 
value 
Linear 
detection 
range 
(mM) 
Current 
for 0.90 
mM 
OA 
(A) 
% difference with 
(PDA-
MWCNT/ACOD/PDA-
MWCNT/ACS) 
Tested with 
plasma/serum 
Sensitivity 
(A/mM) 
R
2
 
value 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS) 
 
1.7222 0.9929 0.1 – 0.9 1.5320 - 5 serum  2.6738 0.9972 
(PDA/ACOD/PDA/ACS) 2.2021 0.9651 0.1 – 0.9 2.0387 33 4 serum  3.8001 0.9661 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PMBN) 
 
1.4505 0.9776 0.1 – 0.9 1.3211 -14 5 plasma 4.7975 0.4555 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PMBN+ATP+CoA) 
1.7383 0.9278 0.1 – 0.9 1.7107 12 5 plasma -1.2018 0.4256 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/BSA) 
 
1.0190 0.9840 0.1 – 0.9 0.9094 -41 5 plasma -0.1047 0.0155 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PDA-
MWCNT/PSS) 
0.8144 0.9909 0.1 – 0.9 0.7168 -53 4 serum 2.3723 0.9134 
(PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PDA-
MWCNT/PMAA) 
0.5372 0.9629 0.1 – 0.9 0.5080 -67 4 serum 1.9237 0.9884 
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5.4.1 Problems with working in blood 
Even after the incorporation of the last layer (as shown as a pictorial scheme in Figure 5-1) in to 
the standard bienzyme electrode, the interferences were not significantly reduced. Biological 
variation of some metabolites (in plasma NEFA) makes the status of healthy individuals hard to 
define in just one reading [355]. There is conflicting information in literature regarding the 
correct time to detect NEFA from patients blood and this varies depending on the method that is 
used for NEFA determination. 
Once the blood is withdrawn from the patient, the NEFA should be analysed at once, this has 
been emphasised by many authors [356-358]. If there is a delay in NEFA extraction and 
detection the results are not representative of the actual NEFA concentration of the patient at the 
time it was withdrawn. Table 5-5 lists the different techniques in literature that have come across 
this problem and the optimum conditions derived for NEFA storage and accurate determination 
that was found. Some studies were done in which two or more techniques of NEFA detection 
were compared, and in which the concentration of NEFA detected increased over time [359, 
360]. Over the other methods, the enzymatic method was chosen in hospitals as it was the easiest 
to do (low training needed) and took the least time, the method could be easily automated, 
reducing the amount of reagents needed and the cost for each analysis, so this was the method 
chosen in hospitals till today [360]. However this enzyme method gives total NEFA levels, and 
the concentration of each fatty acid is unknown [1]. The data obtained from Figure 5-7 has been 
incorporated into the table, the pattern observed in this work follows the norm with regards to 
fluctuations in NEFA detection in blood. 
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Table 5-5: Different methods of NEFA detection and concentration difference during storage. 
Detection of 
NEFA in 
Method of NEFA detection 
Time after which 
analysed 
Storage Information found References 
Plasma and 
serum of 
healthy 
adults 
Extraction, TLC and methylation, 
then quantitated via GC column 
with flame ionization detector 
1-3 days after 
methylation and 
extraction 
at 4 
o
C under 
nitrogen 
3 % change in NEFA concentration [361] 
Whole blood 
Extraction, TLC and methylation, 
then quantitated via GC column 
with flame ionization detector 
2 hours 
at room 
temperature 
At 24 hours in room temperature for the 
unsaturated NEFA the % of control value was 
twice as high as for the saturated NEFA.  
 
Storage at -20 
o
C without nitrogen led to oxidation 
of double bonds in unsaturated NEFA. 
[358, 361] 
48 hours at 4 
o
C 
Plasma 
6 hours 
at room 
temperature 
48 hours at 4
o
C 
10 days 
at -20 
o
C under 
nitrogen 
Serum Extraction then titration [362] 
1 hour 
at room 
temperature 
Increase of total NEFA serum concentrations in 
both samples by 50 % 
[363] 
1 hour frozen 
Plasma 
Comparative study of calorimetric 
method and titration method 
Immediately upon 
separation 
at room 
temperature 
NEFA level rose 
[364] 
2-48 hours after 
separation 
at room 
temperature 
Increase by 100 % within 24 hours 
1-60 days later at -20 
o
C 
Reduction of NEFA after 2-3 days, greatest after 
30-50 days. Further storage had no additional loss. 
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Plasma 
Extraction into organic phase, 
purification with silica, dried then 
derivatised via GC column with 
dual flame ionization detectors 
Immediately upon 
extraction and 
assay 
at room 
temperature 
Used as control 
[158] 
24 hours at 4 
o
C 8 % increase 
1 hour 
at room 
temperature 
22 % increase 
1 month at 15 
o
C 6 % decrease 
Plasma 
Commercial NEFA-C test Wako 
enzymatic kit 
1 month at -18 
o
C No change in the total amount of NEFA [360] 
Plasma 
Extraction then titration [362] 6 months 
at room 
temperature 
4 fold increase in NEFA concentrations 
[359] 
Extracted, saponified, dissolved 
and titrated [365] 
6 months 
at room 
temperature 
NEFA concentrations fell sharply and activity 
disappeared after 2/3 months 
Serum Ether extraction  at 4 
o
C Storage in fridge resulted in rise in NEFA level [366] 
Plasma and 
serum 
Separation and titration 
Immediately upon 
separation 
at room 
temperature 
Best 
[367] 1 hour at 4 
o
C Gave lower reading 
24 hours to 4 days at 4 
o
C 
Once sample is separated, similar results within 
this time period 
Plasma 
Extraction, then quantitated via 
GC column with mass 
spectroscopy 
10 hours at 4 
o
C Stable 
[58] 1 to 7 days at -20 
o
C Stable 
3 months at -80 
o
C Increase levels by 30 % 
Plasma Chronoamperometry 1 hour at -80 
o
C 
In 3/6 of samples increase in concentrations by 
over 100 % 
This work 
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5.4.2 Why does NEFA concentration increase over time? 
NEFA binding with albumin, can cause underestimation of plasma NEFA [368]. Therefore a 
small percentage of NEFA in plasma cannot be dissociated from albumin, and cannot take part in 
the reaction to quantify the NEFA concentration. 
Lipoprotein lipase (LPL) is released by heparin from the endothelium and causes the breakdown 
of circulating triglycerides to NEFA via hydrolysis [369, 370]. This lipolysis continues in vitro, 
producing artificially high NEFA concentrations [82]. The lipolytic activity needs to be inhibited 
to stop this, for example with the use of tetrahydrolipstatin during storage of sample [369]. Once 
the sample is taken, instant freezing of the plasma sample does not limit the in vitro lipolysis. 
Structure of the compound is shown in Figure 5-11 below. 
 
Figure 5-11: Structure of tetrahydrolipstatin [371]. 
There have been different results reported for the breakdown of phospholipids once plasma has 
been incubated [372]. Work done by Dole showed that before extraction, plasma incubated at 37 
o
C increased the acidity by 35 Eq/L [362]. The cause was found to be enzymatic hydrolysis of 
esterified fatty acids. The increase was prevented by adding 0.1 M CuSO4 or ethanol. The 
conversion of lecithin to lysolecithin accounted for the rate of release of the fatty acids [373]. In 
many of the experiments, most of the acidity determined is a feature of the albumin-bound fatty 
acids, as there is little/no hydrolysis of triglyceride happening in the extraction or titration steps 
that follow [362]. A few proteins other than albumin can bind to NEFA, however none bind as 
much or as tightly as albumin [352]. Numerous intracellular proteins such as the cytoplasmic 
fatty-acid binding protein can bind to NEFA, the same with fructose 1,6-diphosphate-1-
phosphatase and acetyl coenzyme A carboxylase. Catecholamines (e.g. norepinephrine and 
isoproterenol) are key stimulating agents of lipolysis [374]. They have been infused in vivo to 
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study the release of NEFA in plasma, and can be used in vitro to stimulate the release of NEFA 
in adipose tissue or adipocytes in culture. 
 
The norm concentration of NEFA also differs depending on what nutritional state of the patients 
the samples are collected in. As in, whether the patients are healthy or diabetic, whether they 
were fasting or not and whether they were exercising at the time of sampling or not. The variety 
of means has resulted in the widespread of norm values in literature [356]. After a carbohydrate 
meal, the metabolism of carbohydrates provides the heart with its energy, and the NEFA levels 
drop low, with myocardial extraction of NEFA decreasing, but in a fasting scenario, non-
carbohydrates (fatty acids) provide myocardial energy [375]. In a study by Rothlin and Bing, 
random patients plasma samples were taken from a hospital after a 12 hour fast, oleic acid 
concentration was found higher in these patients compared to the study done by Dole et al. in 
which similar concentrations of palmitic and palmitoleic acid concentrations were found in 
healthy subjects [86, 376]. The changes are due to different rates in myocardial uptake of 
individual NEFA. Plasma NEFA concentrations are higher in patients with T2D, obesity or 
insulin resistance [369]. As NEFA provide immediate supply of energy to muscles and the heart, 
this also needs to be considered when quoting concentrations of NEFA from different patients.  
There is a lack of relationship between plasma NEFA concentrations and other measurable 
variables, questioning the daily reproducibility within individuals of NEFA concentrations [49]. 
Both the NEFA concentration and its flux through the circulation varies widely from hour-to-
hour, dependant on nutritional state and physical activity (greatly controlled by hormonal, 
metabolic and neural signals) [81]. In one study fasting samples were taken from 12 healthy 
individuals on consecutive mornings and NEFA was determined using the Roche Applied 
Science colorimetric method [355]. The same method used in the optical validation work in 
section 5.2. The results in that study had very high variability (within person the biological 
coefficient of variation was 45 % for NEFA, compared with lactate 31 %, triglycerides 21 % and 
glucose 4.8 %). The results implied that plasma NEFA concentrations generate ‘almost random 
numbers!’ [49]. Biological variation may be due to variation in: assays, technique (e.g. patient 
blood sampling), day-to-day conditions and biological status of an individual. Making NEFA 
concentrations not the ideal marker for epidemiology [72]. 
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Another important factor is time. The quality of the result is degraded if the sample is not 
transported and analysed in time [339]. 5 % stability loss is the maximum permissible storage 
time [341]. An elevated concentration in vitro is not just a problem for NEFA determination. 
Other research has been done on other biomarkers such as glucose and lactate in which the 
concentration of the analyte shifted over time. With limited oxygen supply glucose is converted 
to lactic acid by anaerobic metabolism, reducing glucose concentration and subsequently 
increasing concentrations of lactate and H
+
 [339]. The reaction speed is proportional to the 
temperature, time and amount of metabolically active cells in the sample. To stop these 
metabolic changes, glycolysis inhibitors should be present in the sampling tube. Albumin and 
other plasma proteins are very stable, so will still be present as interference in the work. Always 
resulting in a lower current response. 
Factors influencing measured NEFA biomarker levels [84, 85]: 
 Age and sex – effects of growth hormone and oestrogen levels 
 Dietary intake 
 Supplement use by individual 
 Sampling site, procedure, amount sampled (detection limits), sample handling and 
storage 
 Analytical method 
 Lipolysis/fasting state of individual 
 Status of nutrition 
 Lipogenesis 
 Diseases affecting measurement (e.g. cystic fibrosis, liver cirrhosis, diabetes, zellweger 
syndrome). 
All these factors need to be taken into consideration when working out NEFA biomarker 
concentrations. Having a study that is consistent in the group/type of people who donate 
plasma/serum for NEFA detection is paramount to the future of any NEFA biosensor 
development.  
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It is unknown what disease state these donors (people who donated their blood for this study) 
were in/if any, leading to the complication in getting a consistent reading with varying NEFA 
concentrations. The donors may have been in completely different disease states, or having 
elevated concentrations of other compounds in their blood which would have caused interference 
on the fabricated electrode, e.g. ascorbic acid.  
In future taking blood from the same sample of donors would provide more consistent data for 
the sensor in reading concentrations of blood NEFA within certain conditions. In a practical 
application, some sensors are prone to certain interferences which are present at high enough 
concentrations in the patients blood. These sensors would state in the information manual 
provided that the sensor would not be suitable for patients suffering from that disease because of 
a specific interference or increase in concentration of a compound. 
 
It would have been useful to have had the concentration of glucose/ascorbic acid/uric acid 
worked out (via assays) for each plasma/serum sample. This would have shown how much the 
concentrations of each patients had differed and if that difference was causing the difference in 
NEFA levels determined via CA. 
Having a finger prick sensor would give instantaneous results of NEFA, when compared to the 
current method used in hospitals which involves transportation of sample across a city or region 
to get it tested via the optical UV method. In addition, compare the time taken for CA at 500 mV 
after 500 s vs. the 35 minutes plus for the current UV method to give the NEFA reading in the 
concentration of blood sample. 
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5.5 Conclusions 
 
The aim of this chapter was to fabricate an enzyme electrode based on the original bienzyme 
electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 to keep interferences in blood to a 
minimum.  
Many enzyme electrodes were fabricated using LbL method on C-SPE, including the use of 
PMBN, BSA and the polymers PSS and PMAA. Calibration plots were first obtained with 
different concentrations of OA standard using CA at a set potential of 500 mV for each 
fabricated electrode. After the original electrode, (PDA-MWCNT/ACOD/PDA-
MWCNT/ACS/PDA-MWCNT/PSS)1 had the highest linearity for CA (with R
2
 of 0.96) and 
LSV (with R
2
 of 0.99). 
The linear detection range of each of the new fabricated electrodes was the same as the reference 
electrode, 0.1 mM to 0.9 mM OA. 
The choice of whether to test in serum or plasma was also investigated. Serum and plasma 
samples were tested electrochemically to detect the NEFA concentrations. The actual NEFA 
concentration in each blood sample was pre-determined using the UV method from following 
either Roche Applied Science or Wako Diagnostics protocols. 
The problems of working in blood for NEFA detection were highlighted, along with reasons as 
to why there are major fluctuations within reproducibility using the same blood sample. This 
problem had been encountered by many authors for a range of NEFA detection techniques. 
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6 Conclusions and recommendations for future work 
6.1 Conclusions 
The development of an electrochemical biosensor for NEFA is feasible. The oxidation of H2O2 
was detected using 3 SPE’s from the enzymatic reaction of acylated NEFA and the enzyme 
ACOD (step 2 of scheme 1). This showed linear, reproducible calibration graphs. 
Enzyme electrodes were fabricated to lose having the enzyme ACOD in solution. (PDA-
MWCNT/ACOD)2 was the first enzyme electrode fabricated based on LbL method. This also 
gave linear corresponding current which was detectable using LSV. The main bienzyme 
electrode was (PDA-MWCNT/ACOD/PDA-MWCNT/ACS)1 which was used throughout the 
study as the standard enzyme electrode, due to its reproducibility and linearity. This fabricated 
electrode now eradicated the use of both ACOD and ACS in solution, only leaving the addition 
of solutions of ATP and CoA to complete the enzymatic reaction and produce H2O2. The 
different electrode combinations and enzyme ratios were investigated leaving a chosen method 
for future work. The compound NEM was dropped from the NEFA sensor development as it was 
not needed for electrochemical NEFA detection (saving potential cost and time). 
Multiple enzyme electrodes were fabricated on C-SPE and tested with serum/plasma samples for 
NEFA detection. The most promising electrode was with the addition of PMBN as a blocking 
agent to potential interferences in human blood. 
The expected product will help researchers know more about the metabolic information in the 
patients and ultimately improve their lifestyle by helping them track and monitor their blood 
NEFA levels in addition to their blood glucose levels. NEFA detection is much less studied in 
comparison with glucose. Opening up a pathway for a new market for this sensor development. 
But before the sensor can be developed any further, work needs to be done on the reproducibility 
of NEFA concentrations in blood, in both the optical method (as validation) and in the 
electrochemical method presented. The optimal method of blood extraction, storage and 
reproducibility needs addressing, as this has been found as missing in literature. 
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6.2 Recommendations for future work 
The most simplest and common types of biosensors consist of H2O2 detection [377]. So with 
keeping this in mind, further work can be suggested. 
As there was no effective blocking membrane found for NEFA detection, other compounds 
could be investigated. Nafion could be used as a blocking membrane to prevent interferences 
passing through [378]. It contains two different regions (hydrophilic polymer backbone and 
outside the hydrophobic region, the hydrophilic sulfonate groups) [209]. Nafion provides 
electrostatic repulsion, by being a negatively-charged perfluorinated ionomer, successfully 
limiting the anionic interferents from adhering to its surface [379]. It also reduces the rate of 
biofouling [380]. Nafion has been used extensively in amperometric biosensors (e.g. in glucose 
sensors as the outer coating [338]) and can be applied to this current fabrication system. Nafion 
can be used to solubilize CNT giving effective electrocatalytic action of CNT towards H2O2 
[268]. Also alternate deposition of nafion and cellulose acetate can be used to eliminate 
interferences [381]. 
As ACOD contains FAD, the well defined direct electrochemical behaviour of flavoprotein-
oxidase systems is extremely difficult due to the FAD moiety deeply embedded in a protective 
protein shell [274]. Direct electron transfer cannot occur from the enzyme to the electrode. 
Mediators are therefore needed. Co-immobilization of enzyme and electron mediator on the 
electrodes surface can give a mediator based biosensor [377]. Mediators can be used to shuttle 
electrons to and from the enzyme and electrode. The mediator is free to move between the 
enzyme active site and the electrode surface, reducing the electron tunnelling distance. A redox 
mediator could oxidize H2O2 or the enzyme ACOD, and then be reduced in turn by the surface of 
the electrode [269]. Good redox mediators should be: 
 small in size and molecular weight 
 independent of pH 
 having its electron transfer properties reversible 
 chemically stable in both forms (oxidized and reduced) 
 immobilized easily 
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Common class or redox mediators used for H2O2 detection is the ferrocenes (Figure 6-1). The 
molecule bis-cyclopentadienyl iron(II) (the full name of ferrocene) has a sandwich-type 
structure, here the iron atom is sandwiched in the middle of two five-membered carbon rings 
[250].  
 
Figure 6-1: Structure of Ferrocene (its derivatives have different functional groups on X/Y). 
 
Ferrocene just as common iron centred inorganic complexes can undertake reversible 1 e
-
 
oxidation / reduction, with the electron transfer rate being extremely quick. 
Fe
3+
 + e
-
  Fe2+      
Fe
2+
  Fe3+ + e-                
However direct electron transfer (without mediators) would be more advantageous, as it helps 
develop reagentless biosensors [382]. 
Due to the high interference of readily oxidizable compounds in blood at 500 mV, CA could be 
done at a lower potential of 300 mV (shown in Figure 6-2). The calibration graph of this at 500 s 
is shown in Figure 6-3. At the lower potential there is lower H2O2 oxidized, however the sensor 
would be less susceptible to interferences such as ascorbic acid, uric acid and acetaminophen. 
The linear detection range at this potential was 0.0 to 0.9 mM OA (the same as that of 500 mV), 
the sensitivity was 0.5072 A/mM and the R2 value was 0.9988. Repeating the blood 
experiments at this lower potential may have been good to provide a comparison. Further work 
could explore the avenue of having a reduced potential of 300 mV. 
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Figure 6-2: CA at 300 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4.  
 
 
Figure 6-3: Calibration graph at 500 s. 
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The reduction of H2O2 can also be investigated. As the potential at which H2O2 oxidises causes 
large interferences, the reduction does not have this disadvantage. H2O2 can be reduced at ~ 0.0 
V by metalized carbon (e.g. rhodium or ruthenium on carbon working electrode) transducers 
[383]. At this potential most undesirable electrochemical reactions of potentially interfering 
substrates are insignificant. 
Currently, the only fatty acids investigated were palmitic and oleic acid. There are many fatty 
acids present in the blood and plasma, which may or may not have an influence on patients with 
T2D or for metabolism studies in general. The structure of the fatty acid will have an effect on its 
detection. Other fatty acids that will may also need to be investigated are linoleic acid (C 18:2), 
which has two double bonds and stearic acid (C 18:0), which is a longer saturated chain 
compared to palmitic acid. 
There has been an increased demand of multianalyte sensing devices [384]. This is very useful 
for energy metabolism biomarkers, or in combining the detection of the different biomarkers in 
one simple sensor, which would work by just one finger prick of blood. Another research interest 
may be to combine NEFA (lipid store) and glucose (carbohydrate store) and have one sensor that 
can detect both, helping the patient manage and control their diabetes better. This is ideal as 
patients already monitor their glucose and there are already third generation glucose sensing kits 
based on electrochemical methods. Personalised intervention programmes for treatment and 
management of T2D would find this sensor useful. Offering more comprehensive information of 
the patients metabolic profile for both patient and clinician, leading to better disease 
management. 
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The future considerations in NEFA sensor development are shown in the mind map below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Problems with working 
in blood, e.g. 
serum/plasma issue 
 
Expensive kits 
and enzymes 
 
Conflicting information in 
literature regarding the 
reproducibility of NEFA levels 
in blood 
 
NEFA present in blood (high interference and patient 
inconvenience), urine (more research needed) and saliva (3 types) 
- Where best to target the sensor? 
 
Best method of validation 
against electrochemistry 
needs to be worked out 
 
Future 
considerations 
for NEFA 
Use of energy 
metabolism studies in 
mammals and humans 
 
Interferences in 
electrochemistry 
at 500 mV 
 
Different NEFA chain lengths 
- Target all or a few? 
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7 Appendix 
 
Publications from this work: 
 Kang J, Hussain A T, Catt M, Trenell M, Haggett B and Yu E H, 'Electrochemical 
detection of non-esterified fatty acid by layer-by-layer assembled enzyme electrodes', 
(2013) 190 Sensors and Actuators B: Chemical. 
 
Oral presentations at conferences: 
 Northern Postgraduate Chemical Engineering conference (NPCEC), Newcastle from 8-9th 
August 2013. Presentation titled ‘Development of non-esterified fatty acid (NEFA) 
electrochemical biosensor for patients with type-2-diabetes’. 
 
Poster presentations at conferences: 
 Biosensors 2012, Cancun Mexico from 15-18th May 2012. Poster titled ‘Electrochemical 
biosensor development for non-esterified fatty acid (NEFA) detection’.  
 Diabetes UK 2014, Liverpool UK from 5-7th March 2014. Poster titled ‘Development of 
electrochemical non-esterified fatty acid (NEFA) biosensor for patient management of 
type-2-diabetes’. 
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Figure 7-1: The factors that contribute towards cardiovascular disease in obesity [385]. 
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Uric acid 
 
 
 
 
 
Figure 7-2 shows the CA at 500 mV for uric acid on the C-SPE. The inset shows a linear 
calibration graph obtained at 500 s. In humans, the end product of purine metabolism is uric acid 
[386]. The major purine nucleosides, adenosine and guanosine get converted to uric acid via an 
intermediate. High serum uric acid is linked with higher risk of T2D, this is independent of 
obesity, dyslipidemia and hypertension [387]. 
The electrochemical oxidation of uric acid occurs at approximately 460 mV, the electrode 
surface is fouled by the oxidation product [304]. Its oxidation is irreversible at glassy carbon and 
metal electrodes and quasi-reversible at a graphite electrode. At pH 7.4 approximately 98 % of 
uric acid is in the form of monosodium salt [388]. 
Uric acid is oxidized (Figure 7-3) in a 2e
-
2H
+
 reaction to an unstable quinonoid diimine species 
(half-life ≤ 22 ms), which in a step-wise fashion gets attacked by water molecules forming an 
anionic imine-alcohol, then uric acid-4,5 diol [304, 389]. This uric acid-4,5 diol is unstable, and 
Figure 7-2: CA at 500 mV for various concentrations of Uric acid measured at a C-SPE in 0.1 M phosphate buffer pH 7.4. 
Inset: Calibration graph at 500 s. 
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depending on the pH it decomposes to various products. The end decomposition product is 
allantoin [282]. 
 
Figure 7-3: Series of reactions that occur with uric acid oxidation [389]. 
 
This is what would have fouled the surface of the C-SPE, rendering it unusable for other uric 
acid concentrations. 
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Ascorbic acid 
Ascorbic acid exists in two ketone tautomers below: 
 
The enol form is less stable. On a bare electrode, the oxidation of ascorbic acid is totally 
irreversible and requires high overpotential [304]. No reproducible electrode response is found 
due to the electrode surface getting fouled by the adsorption of the oxidized product of ascorbic 
acid. Figure 7-4 shows the CA at 500 mV for ascorbic acid on the C-SPE. The inset shows a 
linear calibration graph obtained at 500 s, the electrode surface has not been fouled by the 
oxidation product. 
 
Figure 7-4: CA at 500 mV for various concentrations of Ascorbic acid measured at a C-SPE in 0.1 M phosphate buffer pH 
7.4. Inset: Calibration graph at 500 s. 
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Acetaminophen 
Figure 7-5 shows the CA at 500 mV for acetaminophen on the C-SPE. The inset shows a very 
linear calibration graph obtained at 500 s.  
Acetaminophen is electroactive and previously voltammetric mechanistic studies for the 
electrode processes of the acetaminophen/N-acetyl-p-quinoneimine redox system have been 
done [390]. Its oxidation is reversible during CV. Acetaminophen oxidation is also a 2e
-
2H
+
 
process, shown below: 
 
Acetaminophen causes a large interference on C-SPE due to its highly oxidizable nature. 
 
Figure 7-5: CA at 500 mV for various concentrations of Acetaminophen measured at a C-SPE in 0.1 M phosphate buffer 
pH 7.4. Inset: Calibration graph at 500 s. 
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PDA based electrode for blood detection 
Figure 7-6 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA/ACOD/PDA/ACS)1. The calibration graph in Figure 7-7 shows the results from CA at 500 
s, along with those of 4 serum samples run from the same patient. The UV serum concentrations 
of 0.107, 0.160, 0.240 and 0.360 mM came to 0.125, 0.210, 0.390 and 0.740 mM 
electrochemically. This is a 16.8, 31.25, 62.5 and 106 % increase respectively. The higher the 
concentration of NEFA the higher was the increase of interference. 
 
Figure 7-6: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA/ACOD/ 
PDA/ACS)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4. 
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Figure 7-7: Calibration graph at 500 s. 4 serum samples from the same patient in red. 
 
PMBN based electrode for blood detection 
Figure 7-8 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PMBN)1. The calibration graph in Figure 7-9 
shows the results from CA at 500 s, along with those of 5 plasma samples run from the different 
patients. The UV plasma concentrations of 0.090, 0.216, 0.239, 0.495 and 0.522 mM came to 
0.900, 0.875, 0.940, 0.930 and 0.930 mM electrochemically. This is a 900, 305, 293, 88 and 78 
% increase respectively. All the plasma samples read to similar values electrochemically. The 
interferences were too large to detect the difference in the NEFA concentrations for different 
patients. 
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Figure 7-8: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PMBN)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4. 
 
Figure 7-9: Calibration graph at 500 s. 5 plasma samples from the same patient in red. 
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Figure 7-10 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PMBN+ATP+CoA)1. The calibration graph in 
Figure 7-11 shows the results from CA at 500 s, along with those of 5 plasma samples run from 
one patient. The UV plasma concentrations of 0.240, 0.265, 0.550, 0.580 and 0.610 mM came to 
0.775, 1.080, 0.660, 0.660 and 0.720 mM electrochemically. This is a 223, 308, 20, 14 and 18 % 
increase respectively. This was a great improvement compared to the electrode (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PMBN)1. However similar NEFA concentrations (0.550 
and 0.580 mM) that are distinguishable in the UV method, are not distinguishable in the 
electrochemical method (both showed as 0.660 mM). Increase in concentration of NEFA by 14-
20 % in blood compared to OA standard is the best result in all the fabricated electrodes. 
 
The molecular size of phospholipids is < than of proteins, and the molar concentration of 
phospholipids is > than proteins, therefore phospholipid molecules diffuse from plasma to the 
polymer surface more readily than proteins [391]. On the MPC copolymers surface, 
phospholipids are adsorbed immediately undergoing self-organization and forming a stable 
adsorbed layer that has a surface similar to a biomembrane. 
159 
 
 
Figure 7-10: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PMBN)1 in 0.1 M phosphate buffer pH 7.4 (1 mM ATP and CoA in the PMBN 
layer). 
 
Figure 7-11: Calibration graph at 500 s. 5 plasma samples from the same patient in red. 
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BSA based electrode for blood detection 
Figure 7-12 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/BSA)1. The calibration graph in Figure 7-13 
shows the results from CA at 500 s, along with those of 5 plasma samples run from different 
patients. The UV plasma concentrations of 0.189, 0.279, 0.405, 0.477 and 0.639 mM came to 
0.750, 1.125, 0.870, 0.780 and 1.160 mM electrochemically. This is a 297, 303, 115, 64 and 82 
% increase respectively. Again the interference being highest for the lower concentrations of 
NEFA. 
 
Figure 7-12: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/BSA)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4.  
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Figure 7-13: Calibration graph at 500 s. 5 different patient’s plasma samples in red. 
 
PSS based electrode for blood detection 
Figure 7-14 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PSS)1. The calibration graph in 
Figure 7-15 shows the results from CA at 500 s, along with those of 4 serum samples run from 
the same patient. The UV serum concentrations of 0.107, 0.160, 0.240 and 0.360 mM came to 
0.480, 0.625, 0.740 and 1.225 mM electrochemically. This is a 349, 291, 208 and 240 % increase 
respectively. Using serum samples for the same patient did not reduce the interference 
significantly. The electrode (PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PSS)1 
relies on electrostatic interaction only between the polymers. In comparison to the PMBN 
electrodes, which create a surface similar to a biomembrane, and therefore reduces interference 
significantly. 
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Figure 7-14: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PSS)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 7.4. 
 
Figure 7-15: Calibration graph at 500 s. 4 serum samples from the same patient in red. 
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PMAA based electrode for blood detection 
Figure 7-16 shows the chronoamperometric results for OA at 500 mV for the fabricated electrode 
(PDA-MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PMAA)1. The calibration graph in 
Figure 7-17 shows the results from CA at 500 s, along with those of 4 serum samples run from 
the same patient. The UV serum concentrations of 0.107, 0.160, 0.240 and 0.360 mM were too 
high to be detected electrochemically. This electrode was not suitable for NEFA detection.  
 
With polyelectrolytes which are weak the interaction becomes more complicated, PMAA has 
more negative charges at the pH of 8 compared to that at the pH of 5 [353]. Normally there is a 
1:1 ratio of anionic and cationic groups in polyelectrolyte multilayers, however for weak 
polyelectrolytes (such as in the case of PMAA), overall ratio can differ from 1:1 as not all of the 
monomers need to have a charge [314]. Hence why the performance of this electrode was the 
poorest. 
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Figure 7-16: CA at 500 mV for various concentrations of OA measured at a C-SPE modified with (PDA-
MWCNT/ACOD/PDA-MWCNT/ACS/PDA-MWCNT/PMAA)1 in 1 mM ATP and CoA and 0.1 M phosphate buffer pH 
7.4. 
 
Figure 7-17: Calibration graph at 500 s. 4 serum samples from the same patient in red. 
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